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ABSTRACT

Lee, Chung-Wein. Ph.D., Purdue University, May 2015. A Novel In vivo Tumor Oxygen
Profiling Assay: Combining Functional and Molecular Imaging with Multivariate
Mathematical Modeling. Major Professor: Keith M. Stantz.

Purpose: The objective of this study is to develop and test a novel high spatio-temporal
in vivo assay to quantify tumor oxygenation and hypoxia. The assay implements a
biophysical model of oxygen transport to fuse parameters acquired from in vivo
functional and molecular imaging modalities.
Introduction: Tumor hypoxia plays an important role in carcinogenesis. It triggers
pathological angiogenesis to supply more oxygen to the tumor cells and promotes
cancer cell metastasis. Preclinical and clinical evidence show that anti-angiogenic
treatment is capable of normalizing the tumor vasculature both structurally and
functionally. The resulting normalized vasculature provides a more efficient and uniform
microcirculation that enhances oxygen and drug delivery to the tumor cells and
improves second-line treatments such as traditional radiation or chemotherapy. Early
studies using the overall or average tumor hypoxia as a prognostic biomarker of antiangiogenic therapy efficacy was ambivalent; however, recent studies have discovered
that the etiology of hypoxia and its heterogeneity could be used as reliable prognostic
biomarkers. The capability to longitudinally map tumor hypoxia with high spatial and
temporal resolution has the potential to enhance fundamental cancer research and
ultimately cancer patient care.
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Method: A novel methodology to identify and characterize tumor hypoxia by fusing the
physiological hemodynamic parametric maps obtained from functional and molecular
imaging modalities and technique using a modified Krogh model of oxygen transport
(MPO2) was developed. First, simulations studies were performed to validate this
technique. Microscopy data of tumor and brain tissue (control) provided both the
vasculature and rheology data. A Green’s function algorithm was used to solve the
ordinary differential equation and calculate the oxygen profile at a microscopic scale (15
Pm) (GPO2), which was used as a reference. From this data, simulated physiological
maps (perfusion, fractional plasma volume, fractional interstitial volume) and
hemoglobin status (oxygen saturation, hemoglobin concentration) was used as input to
MPO2 and used to calculate pO2 levels as a function of scanner spatial resolution and
noise. Second, MPO2 was compared to pO2 measurements in xenograft breast tumors
using OxyLite oxygen sensor as a Gold Standard, where DCE-CT and PCT-S images were
acquired to obtain hemodynamic images. Finally, the vascular physiology measurements
obtained from an anti-angiogenic therapeutic study in pancreatic tumors was applied to
MPO2 and compared to therapeutic response.
Results: The simulation results using Green’s function pO2 as standard showed that the
MPO2 model performance was dependent on the spatial resolution (voxel size) of the
images. Sensitivity and error analysis of this model were also investigated in this study.
These oxygen transport simulations results suggest the oxygen saturation and
hemoglobin concentration were two key factors in tissue oxygenation, and concomitant

xxiii
with blood perfusion and tumor metabolic rate. Comparisons of the pO2 profile
obtained from MPO2 and OxyLite probe in MCF7 tumor model demonstrated a
significant correlation and approached a slope of one (after accounting for a few
outliers). Simulation studies implementing the physiological data obtained from the
anti-angiogenic therapeutic study in pancreatic tumors using the MPO2 model agreed
with the experimental findings that blood perfusion is a valuable prognostic biomarker
in therapeutic efficacy. This model also predicted the oxygenation improvement
difference from two vascular renormalization modes (topological normalization and
geometrical normalization).
Conclusion: The results from the simulation and in vivo studies demonstrated the
feasibility of this novel hypoxia assay. Simulation results of the pancreatic tumors
provide an example of the impact the MPO2 model in conjunction with imaging can
provide when evaluating the therapeutic significance of various normalization modes in
anti-angiogenic therapy, and suggests potential approaches to further improve antiangiogenic therapy efficacy.
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CHAPTER 1.

INTRODUCTION

In 2014, over 1.5 million (1,665,540) Americans are expected to be diagnosed with
cancer, 585,720 of which are anticipated to die from cancer. This is 1 out of every 4
deaths. Even though an overall increase in the combined 5-year cancer survival rate
from 49% to 68% has occurred over the past 30 years due to early diagnosis and
improved treatment, cancer rates remain very high, such as for breast and prostate
cancer, or continue to increase, such as pancreatic cancer where prevalence (1.3% per
year) and death rates (0.4%) continue to increase. A critical factor associated with poor
treatment response and contributing to reduced patient outcome is tumor hypoxia. As
demonstrated by the overall increase in cancer 5-year survival rates, the development
of new imaging technologies and methods have shown to significantly impact early
detection and treatment. The objective of this thesis is to advance in vivo imaging and
our understanding of intra-tumor hypoxia and its role in cancer therapy, in particular its
role in anti-angiogenic therapy. In this chapter, hypoxia, its association with
angiogenesis, and its clinical relevance in patient treatment and outcome are discussed.
Existing mathematical models of oxygen transport and diagnostic methods to measure
intra-tumor hypoxia are discussed.
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Finally, a novel 3-D in vivo assay to measure intra-tumor oxygen concentrations,
hypoxia, and forms are hypoxia is proposed by combining imaging and oxygen
transport models.

1.1

Relevance of Tumor Hypoxia

1.1.1 Hypoxia and its Clinical Significance
The definition of hypoxia can vary depending on the biological system under
investigation. For example, a biochemist may define hypoxia as the level of dissolved
oxygen necessary to sustain life on microbial fauna, a physiologist as the level of oxygen
which influences organ function, a radiobiologist on cell survival curves, and oncologists
on clinical outcomes, such as the hypoxic fraction or median partial pressure of oxygen
(pO2). In many cancers, the oxygen or hypoxic microenvironment within a tumor plays a
critical role in a patient’s response and resistance to therapy. Studies have shown that
low levels of oxygen, or hypoxia, deprives cancer cells of hypoxia and confers resistance
to chemotherapeutic drugs and ionizing radiation, leading to treatment failure and poor
disease-free/overall survival rates [1-3][25-28]. This has been observed in patients with
breast, head-and-neck, and cervical cancers, and are more likely to suffer metastasis
and local recurrence if their tumors are determined to by hypoxic [4, 5][29-30]. An in
vivo assay of tumor oxygenation that bridges the gap between the pathologist, the
physiologist and the oncologist would greatly enhance the translational capacity of this
research these disciplines within the clinic.
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1.1.2 Hypoxia and Angiogenesis in Cancer
Tumors growing beyond 1 mm in diameter exceed the maximum oxygen diffusion
length and forms hypoxia [6]. While normal cells typically die under severe oxygen stress
or hypoxia (< 10 mmHg) (e.g., apoptotic pathways) [7], cancer cells have been shown to
survive and transform into a more aggressive phenotype, metastasizing to other parts of
body [8-10]. One critical factor contributing to this phenotype is the cancer cell’s ability
to initiate the formation of new blood vessels or angiogenesis. Unlike normal
angiogenesis observed in wound healing or ovulation, tumor-induced angiogenesis
forms a structurally and functionally abnormal vasculature that fluctuates spatially and
temporally throughout the tumor volume [11, 12]. This resulting vasculature network in
turn contributes to or detracts from the supply (or delivery) of oxygen to the tumor cells,
and when combined with their high consumption and proliferation rates, results in a
local imbalance between the supply and demand of oxygen. Several factors contributing
to this imbalance include: (1) low oxygen partial pressure in arterial blood (hypoxemic
hypoxia); (2) reduced capacity of the blood to carry oxygen (anemia or carbon monoxide
poisoning, e.g., anemic hypoxia); (3) reduced blood perfusion (ischemia) or periodical
fluctuations in blood perfusion (cycling or acute hypoxia); (4) increased oxygen diffusion
distance due to deterioration of local vasculature or elevated levels of interstitial fluid
pressure (diffusion or chronic hypoxia); and (5) inability of cells to utilize oxygen due to
cellular toxicity (cyanide poisoning) (histotoxic or cytotoxic hypoxia). Despite the
advances over the past four decades in our understanding of angiogenesis, the detailed
interactions between angiogenesis, vascular physiology and hemodynamics, and
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hypoxia remain unknown and an active area of research [13, 14]. This is not a surprise
since the simultaneous quantification of oxygen levels and other corresponding
physiological parameter measurements are difficult and in many cases impossible to
obtain.

1.1.3 Angiogenic Biomarkers
As discussed in the previously, tumors are marked by uncontrolled cellular proliferation;
and, as the tumor volume increases, so does the demand for oxygen and nutrients.
Once hypoxia forms, a complex network of biomolecular pathways are initiated, where
various transcriptional factors, genes, and growth factors are up-regulated, in particular
vascular endothelial growth factors (VEGF) and their receptors (VEGFR). Angiogenesis
initiates endothelial cells (ECs) within existing microvasculature to respond by randomly
sprouting neovessels and pruning of existing vasculature (vascular remodeling) [15, 16].
This resulting tumor-induced vasculature appears structurally chaotic and highly
dysfunctional, and fails to provide the extra nutrients and oxygen required by the tumor
cells. The hypoxic status within the tumor becomes exacerbated, and further drives the
tumor cells to secrete additional growth factors. Unlike normal physiological hypoxia
observed in wound healing or new tissue generation, tumor hypoxia leads to a highly
abnormal vasculature and vascular physiology which are causal to genetic instability,
metastasis, immunosuppression, inflammation, cancer stem-cell (CSC) phenotype,
epithelial-mesenchymal transition (EMT), resistance to cell death, and altered
metabolism.
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A key transcription factor expressed under hypoxic conditions is the Hypoxia-Inducible
Factor 1 or HIF-1 [17, 18]. Several key genes related to tumor angiogenesis and
oxygenation regulated by HIF-1 is listed in table 1.1.3.1 Vascular Endothelial Growth
Factor (VEGF) family and their receptors (VEGFR) are the most potent and well
investigated of these pro-angiogenic molecules [19, 20]. In addition to HIF-1, several
other genes, proteins, enzymes, and chaperones related to tumor progression and
therapeutic resistance have also been shown to be activated by hypoxia, such as
glycolytic enzymes, glucose transporters (GLUT1 and GLUT3), and carbonic anhydrase IX
(CA9) [18, 21-26]. Their role in angiogenesis or in cancer progression is under
investigation.

Table 1.1.3.1 Genes regulated by HIF-1
Gene
VEGF 1/2; VEGFR1/2
Notch signaling

Function
References
Hypoxia-induced angiogenesis; cell survival
[27-29]
and growth
Cell differentiation, proliferation, and
[30, 31]
apoptosis
Erythropoietin
Red blood cell production in kidney
[32]
Tie 1/2
Vessel formation, maturation, maintenance
[33, 34]
Differentiation, angiogenesis, tissue
[35, 36]
TGF-E
regeneration
VEGF: Vascular Endothelial Growth Factor; TGF: Transforming Growth Factor

1.2

Therapeutic Approaches Targeting Hypoxia

Over the past several decades, clinical studies have been performed to overcome
hypoxia by increasing tumor oxygen levels (hyperbaric, ARCON, and EPO therapies),
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developing chemotherapy agents cytotoxic to cells exposed to hypoxia, or normalizing
the tumor vasculature.

1.2.1 Hyperbaric, ARCON and EPO Therapies
Hyperbaric, ARCON, and EPO therapies attempt to increase the patient’s overall
systemic levels of dissolved (plasma) oxygen, perfusion, or hemoglobin, respectively,
thereby the overall tumor oxygen levels. Hyperbaric oxygen treatment exposes patients
to an elevated oxygen pressure environment prior to/during RT/CRT, thereby increasing
the amount of dissolved oxygen in the blood plasma delivered to the tumor. This
strategy preferentially affects regions of chronic hypoxia, not necessarily acutely hypoxic
regions, and potentially explains the modest increase (10%) in locoregional control in
HNC patients[32;37]. ARCON treatment targets both acute and chronic hypoxia by
increasing perfusion (nicotinamide) and oxygen partial pressure (carbogen breathing).
Clinical results are promising, a significant increase (>80%) in local control, but this
treatment incurs a number of patient side effects, such as nausea, vomiting, and
confluent mucositis (in 90% of patient population), which limits its clinical applicability
[33]. Erthropoietin (EPO) injections reduce anemic-based hypoxia by increasing the
oxygen carrying capacity (hemoglobin) of the blood. However, locoregional progressionfree survival in cancer patients decreased. Severely anemic patients (< 9g/dL) may
benefit from EPO, but increasing a patient’s hemoglobin level beyond 14 g/dL actually
decreases pO2 levels due to venostasis obstructing perfusion.
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1.2.2 Drugs Toxic to Hypoxic Cells
Tirapazamine (TPZ) is a new genre of drugs cytotoxic to hypoxic cells. TPZ is reduced in
the absence of oxygen to form a free radical, which induces DNA breaks, chromosomal
aberrations, and cell death. In the presence of oxygen, TPZ is oxidized to form a
nontoxic agent. When applied prior to chemotherapy (CT) or chemoradiotherapy (CRT),
an increase in the local progression-free and overall survival rate (60-80%) is observed
(phase I and II studies)[35], but, when TPZ is applied concurrently with CRT, overall
survival rates did not improve,[36] indicating a longitudinal dependency on therapeutic
efficacy. Though promising, an international phase III clinical study was terminated due
to an unexpected toxicity due to (1) activation of TPZ in poorly perfused organs and (2)
poor diffusion of TPZ through hypoxic tumor tissue.

From the above studies, the targeting of hypoxia significantly influences therapeutic
outcome by influencing tumor hemodynamics associated with diffusive (chronic) and
perfusion-based (cycling, acute) hypoxia, and drug delivery. Unfortunately, the above
protocols induce systemic toxicities thereby limiting their effectiveness. A more targeted
approach is to modulate angiogenesis and the resulting vascular physiology and
hemodynamics within the tumor.

1.2.3 Anti-angiogenic Therapy and Vascular Normalization
In 1972, Dr. Judah Folkman proposed a very different approach that targets the tumor
vasculature as a treatment for cancer. His idea was to starve the tumor cells by chocking

8
off the blood supply to the solid tumors [37, 38]. However, in some tumors antiangiogenic therapy (AAT) as a monotherapy did not show benefits in some clinical trials
[39-42]. These puzzling results led to a number of new potential mechanisms, such as
vascular normalization first hypothesized by Dr. Rakesh Jain in 2001 and 2004 [43, 44].
In this section, a brief history describing the formation of the first anti-angiogenic drug
and subsequent clinical studies are presented. These results, or lack of results, from
these studies led to the idea of vascular normalization, from which our 3-D hypoxia
assay will be tested.

In 1971, Dr. Folkman was the first to prove the existence of pro-angiogenic factors that
were released by the tumor cells, and proposed to block their action as a means to
potentiate cancer therapy, e.g., arrest tumor growth [37, 38]. Donald Senger and Harold
Dvorak identified this protein and developed a partially purified form of this protein in
1983, and named it vascular permeability factor (VPF) due to its ability to induce
vascular leakage [45]. By 1989, researchers at Genentech isolated and cloned a protein
mitogenic only to endothelial cells and named it vascular endothelial growth factor
(VEGF)[46], which was later determined to be identical to VPF protein. Studies by Eli
Keshet and Karl Plate (1992) demonstrated that VEGF was highly expressed within
hypoxic regions of a tumor, and postulated that hypoxia was a key environmental
trigger stimulating tumor angiogenesis [47, 48]. In the following years, additional forms
of VEGF and its receptors were discovered, such as VEGFR-1 (FLT-1) by Carlie de Vries et
al (1992) [49] VEGFR-2 (KDR) by Terman et al [50]. Unfortunately, clinical trials of anti-
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angiogenic inhibitors by themselves did not significantly increase a patients’ overall
survival [7]. In was not until 2004 when the first angiogenesis inhibitor, bevacizumab
(AvastinTM), was approved by the FDA, followed by a number of FDA approved antiangiogenic drugs targeting the VEGF-VEGFR pathways (bevacizumab[51],
ranibizumab[52], lapatinib[53], sunitinib[54], sorafenib[55]) and others pathways (e.g.,
PDGF, FGF, c-Kit, VEGFR1, VEGFR2, Tie-1, Tie-2[56, 57]). Approval was predicated on the
results from clinical trials that demonstrated an unprecedented increase in OS for
colorectal patents when bevacizumab was combined with chemotherapy drugs [8] [58].
Unfortunately, clinical studies targeting other cancers have not produced similar results.
For example, in pancreatic cancer patients, an increase in OS was not observed
(2009)[9]; in ovarian cancer patients, an increase in progression free survival (PFS) was
not observed unless used in maintenance therapy (2010) [10-11][59]; and in metastatic
breast cancer patients, an increase in OS was not observed, and in many cases favored
the placebo arm (2010) in spite of an increase in PFS [12,13,14]. In fact, recent clinical
and preclinical studies have suggested that angiogenic inhibitors can increase the
invasiveness (glioma patents; 2009)[15) and metastatic potential (mouse models)
(2009)[16,17,18].

To understand these temporary gains (PFS) without improving overall survival or
invasiveness, the association between a tumor’s angiogenic profile and hypoxic status is
being proposed as a causal factor. Given that preclinical studies showed an increased
benefit by combining antiangiogenic therapy with radiotherapy [60-63], a rationale
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supposition is that angiangiogenic therapy (AAT) may have improved the vascular
function to deliver more oxygen to the tumor cells, to delivery oxygen to more tumor
cells, or both. This would also be true for chemotherapy agents. Such a finding appears
counterintuitive because AAT would also reduce the vascular volume or microvessel
density within the tumor. In 2001, Dr. Jain proposed the vasculature normalization
hypothesis to explain this enigma [44].

Perhaps the most important lesson from the antiangiogenic clinical trials is that the
antiangiogenic agents targeting endothelial cells must combine with those agents
targeting cancer cells to reach appreciable impact on patient survival. Evidence of vessel
normalization has been shown in many preclinical and clinical studies (table 1.2.3.1 and
table 1.2.3.2). Before explaining the vessel normalization hypothesis, an overview of the
molecular mechanisms associated with angiogenesis and pertinent to the phenotype
changes in the microvasculature is discussed. In normal tissue repair or angiogenesis,
pro- and antiangiogenic factors are exquisitely balanced and tightly choreographed.
When pro-angiogenic factors are overexpressed, abnormal sprouting from an existing
vessel (angiogenesis) is initiated, and the resulting newly formed vascular appears leaky,
tortuous, and highly dilated with randomness to their interconnections or network.
Pericytes are loosely attached to the capillaries or missing, and the basement
membrane varies in thickness, lacks uniformity, and has large gaps or pores (Figure
1.2.3.1). The normalization hypothesis suggests that once the excess pro-angiogenic
factors are removed and a balance restored, the vasculature returns to a normal or
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efficient state of functionality, as shown in figure 1.2.3.1. By continuing to remove proangiogenic factors, the loss of vasculature inhibits the delivery of oxygen and nutrients,
the supposition Dr. Folkman used when proposing AAT. However, this lack of oxygen
can reduce the sensitivity of the tumor to radiation, inhibit drug delivery, and initiate a
number of unfavorable biological responses hindering these cytotoxic therapies (e.g.,
cell repair mechanisms, dormancy, cancer stem cells prevalence and maintenance). To
date, the details of why simply removing excess pro-angiogenic factors will
spontaneously lead to vessel normalization and improve therapeutic outcomes remain
unanswered.

To test the hypothesis of vascular normalization, numerous animal studies investigating
the therapeutic response to anti-angiogenic agents has been performed. In various
xenograft and orthotopic tumor models, a temporal response has been observed, which
can start as early as one day after treatment and lasts for up to one week [11, 64-68].
Clinical studies also report a benefit [19, 69], as for glioblastoma patients where
normalization window began on day one and lasted for approximately a month (e.g., a
full course radiation therapy) [70]. Conceivably, the regimen of AAT, stage of tumors,
characteristics of the host organ, and mechanism of angiogenesis and therapeutic
targets all play a role in the duration of the normalization window and the outcome of
the treatment. Clearly, an in vivo assay that can reliably identify biomarkers associated
with vessel normalization and the methods to measure and monitor the normalization
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Table 1.2.3.1 Preclinical AAT induced tumor vessel normalization
Agent

Tumor model

Effect on vessel structure

Effect on vessel function

p Diameter

p Permeability [72]

HER2 + breast
Trastuzumab
carcinoma
Gefitinib/PI-103

Fibrosarcoma

p Tortuosity, n PVC

n TBF/oxygenation [73]

DC101

Pancreatic carcinoma

p Vessel volume

n TBF [74]

Palomid-529

Glioma

p Tortuosity

p Permeability [20]

Agent

Tumor model

Effect on vessel structure

Effect on vessel function

p Diameter

p Permeability [72]

HER2 + breast
Trastuzumab
carcinoma
Gefitinib/PI-103

Fibrosarcoma

p Tortuosity, n PVC

n TBF/oxygenation [73]

DC101

Pancreatic carcinoma

p Vessel volume

n TBF [74]

Palomid-529

Glioma

p Tortuosity

p Permeability [20]

HER2: human epidermal growth factor receptor-2; TBF: tumor blood flow; PVC:
perivascular cell coverage. Reference numbers are listed in parentheses.
Table 1.2.3.2 Clinical AAT evidence demonstrating tumor vessel normalization
Tumor type

AAT agent

Effect on vessel structure

Effect on vessel function

Rectal carcinoma (n = 32)

Bevacizumab

p Vessel Density, n PVC

p TBF, p IFP [19]
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Table 1.2.3.2 Continued
Gliobalstoma (n = 31)

Cediranib

p Vessel size

p Permeability [70, 75]

High-grade glioma (n = 5)

Bevacizumab

p Vascular arcades and

[76]

glomeruloid vessels
Prostate Carcinoma (n =

Androgen

Pruning immature vessel, n

10)

ablation

PVC

HER2 + breast cancer

Lapatinib

p Tortuosity

[77]

[78]

brain metastates (n = 22)

AAT: antiangiogenic therapy; PVC: perivascular cell coverage; IFP: interstitial fluid
pressure; TBF: tumor blood flow; HER2: human epidermal growth factor receptor-2.
Patient numbers are indicated in parentheses of tumor type.

1.3

Diagnostic Methods Used to Assess Hypoxia

Identifying reliable prognostic or surrogate markers of hypoxia is a priority in cancer
research and therapy, affecting treatment response and metastatic progression.
Standard clinical procedures are highly invasive, where a polarographic needle electrode
[79, 80] is inserted into the tumor or a biopsy and subsequent histological analysis is
required. These techniques when applied to preclinical and clinical studies found that
the spatial and temporal heterogeneity of hypoxia closely link to the poor outcome of
cancer therapy, but quantifying the heterogeneity remains a challenging task. Recently,
several imaging methods and modalities are currently under investigation to noninvasively assess tumor hypoxia, both directly and indirectly [81, 82]: PET/SPECT, MRI,
Optics, thermoacoustics, dynamic contrast imaging.
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1.3.1 Invasive Methods
The polarographic needle electrode (or Eppendorf pO2 histograph) is the clinically
accepted gold standard method to measure pO2 levels in vivo. This instrument is based
on electrochemical reduction of oxygen resulting in a current proportional to the
amount of dissolved oxygen (DO) present in the tissue. At the tip of the needle consists
of a gold cathode and silver-silver chlorine anode. Near the Au electrode, oxygen
reduces to form water, thus consuming oxygen, which is then oxidized (AgCl) at Ag
electrode resulting an electrical current across the electrodes. A Teflon semi-permeabile
tip prevents tissue proteins from contaminating the tip as enters the tumor. To minimize
the effects of oxygen consumption, the probe acquires pO2 measurements within <1.4
second. During insertion of the needle measurements are taken in 0.7mm steps along
the trajectory of the needle, where the needle moves 1.0 mm forward and 0.3 mm
reversed to minimize physical disruption to the tissue (blood vessels). Variations in pO2
are represented by a histogram. In clinical studies, a median-pO2<10 mmHg or a high
hypoxic fraction (HF<2.5, 5.0mmHg or HF2.5, HF5) is correlated to a lower overall and
recurrence-free survival rate. In spite of its ability to directly measure pO2, the
Eppendorf probe cannot differentiate between chronic and acute hypoxia and is not
widely used due to its invasiveness, lack of spatial information, a low signal-to-noise at
low pO2 levels, and inability to distinguish necrotic from hypoxic regions.

Another oxygen probe device to measure local pO2 is OxyLite probe system (OxyLite,
Oxford Optronix, Oxford, UK). It operates on the principle of fluorescence lifetime of
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ruthemium chloride is oxygen level dependent; the lifetime of fluorescence is inversely
related to the amount of oxygen at the tip[83]. The comparison of pO2 measurement in
normal and tumor tissue between OxyLite and the standard, polarographic needle
electrode, was reported[84-86]. The correlation is better when pO2 is less than 40
mmHg.

1.3.2 Histology
Current clinical methods to assess tumor hypoxia is by performing a tumor biopsy and
immunohistochemical (IHC) staining for exogeneous (pimonidazole, EF5) and
endogenous (HIF1a, GLUT-1, CA9) biomarkers. Two exogeneous biomarkers used
clinically to identify tumor hypoxia are pimonidazole and EF5. These 2-nitroimidazoles
undergo bioreduction in the absence of oxygen to produce reactive intermediates.
Under hypoxic conditions, the reactive products bind covalently to intracellular
macromolecules, while in the presence of oxygen the reaction is oxidized back into its
original form. Therefore, the amount of stable adducts retained in the cells is a measure
of the lack of oxygen present in the cells. To assess tumor hypoxia, these agents are
injected 24-48 hours prior to acquiring a biopsy, after which, immunohistochemistry or
immunofluorescence imaging provides a relative measure of tumor oxygenation. In
some clinical studies, pimonidazole and EF5 binding (median-pO2, HF2.5 or HF5) did
correlate with locoregional tumor control and disease-free survival [87]and event-free
survival time[88], while in other studies the correlation is weak or insignificant. This is
most likely due to the probe being more sensitive to chronic hypoxia. Histological
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assessment of the staining pattern of these biomarkers is consistent with long diffusion
lengths, consistent with chronic hypoxia, which is accentuated by acquiring a biopsy 1-2
days after injection primarily due to pimonidazole and EF5 pharmacokinetics. This
explains, in part, why in some studies pimonidazole or EF5 binding did not correlate with
Eppendorf probe measurements[89, 90]. Overall, the strengths of these exogenous
probes are their ability to measure hypoxia at the cellular level, monitor spatial
heterogeneity (if extirpated), provide relative oxygen concentrations, and predict clinical
outcome. Its drawbacks are its invasiveness, preference to assess chronic hypoxia, and
complex calibration (including ex vivo calibration) if absolute pO2 measurements are
desired.

The primary endogenous protein activated by low oxygen concentrations is the
transcriptional factor hypoxia inducible factor 1, HIF-1. HIF-1 is a heterodimer consisting
of a HIF-1D and a HIF-1E subunit, where the latter is targeted for proteasome
degradation under normoxic conditions. In vitro, HIF-1D protein levels in cultured cancer
cells are tightly regulated by oxygen levels; however, in vivo, HIF-1D expression in
tumors is weakly correlated or lack correlation to pO2 (Eppendorf probe). This is
primarily due to additional mechanisms influencing HIF-1D stability, such as the tumor
microenvironment (acidosis, pyruvate and lactate, glucose), growth factors (IGF-2 and
NO), and genetic mutations or oncogenes (VHL, p53, and PTEN). Under low oxygen
levels HIF-1D remains stable and transactivates over 70 genes that attempt to increase
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the availability of oxygen to the tumor or modulate the metabolic activity of the cancer
cells. The most widely studied proteins are VEGF (angiogenesis and metastasis), GLUT-1
(glucose metabolism), CA IX (pH microenvironment), and EPO (hemodynamics). Each of
these downstream targeted genes of HIF-1D range in their significance as a prognostic
indicator[91-93], but when combined into a single multivariate statistic it strengths in
significance and provides a glimpse into the tumor oxygen microenvironment. For
example, HIF-1

stabilizes within minutes under hypoxic condi
tions decreasing quickly

(<30 minutes) upon reoxygenation; GLUT-1 peaks approximately 16 hours after hypoxic
insult increasing with distance from the blood vessels; and CA IX remains stable 16-92
hours under low oxygen conditions and is predominantly found in poorly perfused
regions. Each of these factors is influenced under different forms of hemodynamics, and
hypoxic-type.

The above techniques are (1) invasive, which significantly and permanently damage the
tissue; (2) cannot distinguish between the different types of hypoxia; and (3)
represented as tumor-averaged values, difficult or unable to link with in vivo function.
These measurements, though useful, provide an incomplete picture of tumor hypoxia,
such as those factors leading to different types of hypoxia, variations in these factors
within the tumor, and the involvement of these factors in reoccurrence and metastasis
of cancer.
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1.3.3 Microscopy
Optical microscopy has often used to scan the detailed structure and function of
microvasculature with submicron resolution. The microscopic measurement has been
shown to reveal insights into the mechanisms of oxygen transport, but due to its limited
resolution at depth, it cannot be used in clinical diagnosis except for surface imaging
(e.g., melanoma). As an example, intravital confocal microscopy integrated with various
techniques has been used to acquire microvessel functions and structures at various
depth[94, 95], but with a penetration depth of confocal of 150-300 Pm (see Chapter 3).

1.3.4 PET and SPECT
An in vivo imaging technique measuring hypoxic implements radiopharmaceuticals
based on 2-nitroimidazoles ligands (e.g., pimonidazole and EF5) conjugated to PET (18F
or 124I) or SPECT tracers (123I or 98Tm)[81, 82, 96]. Several different derivatives of this
structure have octanol and water partition coefficients, e.g., compound solubility in
octanol (non-polar solvent) to that in water(polar solvent), close to 1, which allows
these tracers to be homogeneously distributed in the body one hour after injection [97].
In addition, their distribution is significantly impacted by reduced blood flow [98, 99].
Like their histological counterparts, these tracers are sensitive to tissue hypoxia at the
micro-regional level. Studies using 18F-MISO or 64Cu-ATSM demonstrate that a tumoraveraged signal relative to muscle correlates to therapeutic response and poor outcome
to radiation and chemotherapy [100]. The drawbacks of this technique include limited
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spatial resolution afforded by PET, pharmaceutical effects due to radiation and
dependences on washout kinetics, and poor temporal response (e.g., chronic hypoxia).

1.3.5 MRI
Several MRI techniques, such as Blood Oxygen Level Dependent (BOLD), can measure
tumor hypoxia. These methods are attractive because they are noninvasive, do not
require the need for a short-lived radioactive reporter molecule, and can have good
spatial (~1.0 mm) and temporal resolution (50 ms) [101] thus allowing tumor
oxygenation to be monitored in real-time tumor and changes during treatment. The
BOLD signal measures the amount of deoxyhemoglobin in the blood, which the
paramagnetic iron (Fe2+) enhances the transverse (T2) and apparent transverse (T2* )
relaxation rates from water in blood and in tissue surrounding the blood vessel [102].
No reliable pO2 conversion from T2* is available for BOLD MRI because of the extreme
sensitivity of T2* to the basal state of tumor oxygenation and to many other physiological
parameters, such as pH or blood flow [103]. Therefore, BOLD has been unable to
provide a quantitative measure of pO2 (SaO2) in tumors [104] and the sensitivity
decreased as spatial resolution increased[105]. Another recently developed method
utilizes oxygen-sensitive reporter molecules for MR oximetry, in particular
perfluorocarbons (PFCs). The PFC signal was found around the periphery of tumors after
intravenous injection[106]. New echo-planar imaging methods termed FREDOM after an
intra-tumor injection of PFC was able to form pO2 maps in a tumor and revealed good
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correlation with oxygen electrodes over time [107, 108]. However, a number of
limitations exist, in particular the toxicity from PFCs and the reduced precision of pO2
measurements when pO2 drops below 10mmHg [109, 110]. As with PET, research
groups are labeling 19F with 2-nitroimidazoles. It has shown to have a similar sensitivity
to that of proton MRI and a small endogenous background signal; however, it requires
long data acquisition.

1.3.6 Optical Imaging and Spectroscopy
Near infrared optical spectroscopic techniques based upon the characteristic absorption
properties of hemoglobin molecules is widely used to measure hemoglobin
concentration (CtHb) and oxygen saturation(SaO2) in biological tissue[111]. Studies
demonstrate that this technique can be used to measure the hemoglobin distribution
and oxygen saturation in breast, brain, limb and joint studies [112, 113]. However, the
absorption and scattering of light by tissue limits its spatial resolution and sensitivity as
a function of depth making it difficult to provide local, quantifiable results.

1.3.7 Photoacoustic Tomography and Spectroscopy
Optical imaging techniques possess superior lateral resolution, but suffer poor axial
resolution as a result of photon absorption and scattering in opaque medium
propagation. The lateral and axial resolution also decays drastically as photons travel
deeper. Biologists or physicians are always interested in detecting the tissue
morphology and physiology in deep tissue. Bowen et al first recognized the potential of
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applying the photoacoustic (or thermoacoustic) effect in imaging to mitigate the
intrinsic scattering limitation in soft tissue from optical or NIR light [114, 115]. When
pulsed energy is absorbed by the body, this absorbed energy is converted to heat,
increases the local temperature, results in a subsequent volume expansion, and
generates a broad-band acoustic wave (see figure 1.3.7.1). A transducer array is used to
detect these ultrasound signals. Hence a basic photoacoustic imaging instrument is
composed of two main components, a pulsed light source (Laser) and an array of
transducers to detect acoustic signals. The photoacoustic scanners used in the studies
implement a spherical transducer array to obtain as close to 2S projection of the tumors.
These scanners implement a modified 3-D Radon transformation algorithm to
reconstruct a volumetric image of the tumor [116]. These thermally-generated acoustic
waves and resulting volumetric absorption maps provide a number of key advantages,
such as increased sensitivity compared to optical energy in tissue and improved spatial
resulting due to less tissue scattering.

In angiogenesis and hypoxia research, photoacoustic imaging provides in vivo
measurement of tissue oxygen saturation levels (SaO2) and hemoglobin concentrations
(CtHb), two key vascular physiological parameters in the transport of oxygen to the
parenchyma cells by the microcirculation system. Similar to optical spectroscopy, each
biomolecule has an intrinsic absorption spectrum define by its molar extinction
coefficient, H(O). Due to the change in the absorption spectrum between deoxygenated-
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hemoglobin and oxygenated-hemoglobin, spectroscopic methods can be employed to
obtain both CtHb and SaO2 levels. To acquire CtHb, photoacoustic images are acquired
at the isosbestic wavelength (796 nm) of hemoglobin, where the molar extinction
coefficient is independent of the hemoglobin’s oxygen status (see figure 1.3.7.2). By
acquiring photoacoustic images at wavelength ranging from 680 to 950 nm, spectral
deconvolution algorithms are applied to estimate the SaO2 of the blood within the
tumor’s blood vessels. By considering the hemoglobin absorption spectrum as the
linear combination of oxy- and deoxy-hemoglobin spectra (figure 1.3.7.2), the SaO2 can
be derived by fitting the measured data to the following the equation for Pa (O ) ,

P a (O ) C tHb  SaO2  H HbO 2 (O )  (1  SaO2 )  H Hb (O ) ,
where H HbO 2 (O ) and H Hb (O ) are the extinction coefficients of oxygenated and
deoxygenated hemoglobin at wavelength O .

In summary, photoacoustic tomography is a non-ionizing, fast scanning (3-12 seconds),
noninvasive imaging modality employing laser-induced ultrasonic signals within the
biological tissue. Similar to NIR optical spectroscopy, photoacoustic computed
tomography spectroscopy (PCT-S) provides both CtHb and SaO2 but significantly
increases depth of imaging and spatial resolution based upon the center frequency of
the ultrasound transducer. In addition to diffusion-limited chronic hypoxia in tumor, it
has been shown that tumors also experience acute intermittent cycling hypoxia which
could contribute to tumor metastasis [117, 118]. With Endra scanner, fast PCT-S scans
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surface area product, and other parameters unique to each organ. DCE technique
implements a fast acquisition scanner, the administration or controlled injection of a
(inert) contrast agent, and pharmacokinetic models from which the vascular
physiological parameters are estimated by fitting the time-resolved image intensities
(see figure 1.3.8.1). This concept was first applied to CT by Axel et al (1980) to
simultaneously acquire the morphological and local functional status in brain tissue
[121], as in MRI [122], ultrasound [123, 124], and PET [125]. For the research in this
thesis, a standard methodology for DCE-CT has been developed, where the combined
spatial-temporal resolution can be obtained, the contrast-to-noise ratio (CNR) is
sufficient to measure sufficiently low fractional plasma volumes and perfusion, and the
linearity between the CT signal in Hounsfield units and the contrast agent concentration
is over a wide dynamic range necessary for tumors. By contrast the signal intensity of
DCE-MRI is not linearly correlated to the contrast agent concentration, the signal
intensity or CNR can depend upon many parameters in imaging sequence, and the
influence of water exchange introduces additional parameters into the analysis, all of
which complicates its implementation and introduces uncertainties.
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perfusion, permeability, fraction of plasma volume, and fraction of interstitial volume)
and hemoglobin status (hemoglobin concentration and oxygen saturation), from which
the tissue oxygen concentration based on oxygen transport models can be obtained on
a voxel-by-voxel basis. Dynamic contrast-enhanced computed tomography (DCE-CT) has
been reliably used to quantify intra-tumor heterogeneity in vascular physiology for
different tumors, including breast, pancreatic, ovarian, prostate and glioma cancer [127129]. Similarly, photoacoustic CT spectroscopy has been used to measure the local
distribution of SaO2 and hemoglobin concentrations (CtHb) in tumors. Given the similar
spatial resolution of PCT-S and CT, the image volumes obtained from these modalities
and their ability to highlight tumor vasculature (angiography) enables accurate image
co-registration from these two modalities. Biophysical models will be used to fuse this
information to obtain pO2 levels.

1.4

Oxygen Transport Models

To develop a 3D assay of tumor hypoxia, a link between the microscopic (histology,
invasive probes) and the macroscopic (imaging or scanner modalities) will need to be
established. This will be accomplished through the use of oxygen transport models.

Oxygen and nutrient transport in the body occurs at a macroscopic and microscopic
level. Macrocirculation is composed of the major arteries and veins, and rapidly
transports oxygen and other substances toward or away from various organs.
Microcirculation consists of arterioles, capillaries, and venues and is responsible for the
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delivery and exchange oxygen and nutrients within the surrounding tissue [130, 131].
Pathological microvascular is structurally abnormal or chaotic and highly dysfunctional,
and is unable to deliver sufficient oxygen to tissues or tumors. Unlike other metabolic
molecules, oxygen cannot be stored in the body (myoglobin in muscle is the only
exception); hence, the adequate delivery of oxygen by the microcirculation system to
the parenchymal cells at any given time is critical. Oxygen is either dissolved in plasma
or bound to hemoglobin within red blood cells (RBC). Since oxygen has a low solubility in
plasma, the majority of oxygen (98%) is carried via binding to hemoglobin. In addition to
the blood hemodynamics, the topology of microvascular network, the barriers to oxygen
diffusion barriers when crossing the vessel wall to the parenchymal cells, and oxygen
metabolism rates all affect the local oxygen concentration.

A unique feature in the field of oxygen transport is the rich history of mathematical
models. These models are simple in concept, where they are based on the physical laws
of gas transport in fluids and mass conservation, but can also provide some predictive
capability in determining tissue oxygen concentrations with modest input information.
In many situations, it is difficult and sometimes impossible (depending on the extent of
experiment) to conduct an experiment to simultaneously quantify the oxygen
concentration and the relevant vascular physiology from a single vessel segment. Thus
using a kernel of mathematical models can provide insight into the mechanisms of
oxygen transport. August Krogh and Erlang first developed an ideal cylindrical model to
study mechanisms of tissue oxygenation in a static or quiescent muscle almost a century
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ago [132, 133]. Although Krogh had made a number of assumptions, the mathematical
equations derived from his model set the stage for almost all subsequent theoretical
works. Even with today’s technology, the ability to simultaneously determine key
biophysical or biochemical processes related to oxygen transport in microcirculation
remains under investigation. However, the three key factors underlying these models of
oxygen transport within tissue remain the same: (1) delivery and release of oxygen
within the blood vessels, (2) diffusion of oxygen out of the blood vessels and into the
parenchyma, and (3) rate of oxygen metabolism. An overview of these mechanisms is
discussed, while the underlying foundations of our multivariate biophysical model of
tissue oxygenation (MPO2) will be detailed in Chapter 3.

The main carrier and delivery mechanism of oxygen is through its binding and release
from hemoglobin in blood. The hemoglobin protein has four subunits, each with a heme
group and a globin chain. The heme group is composed of a porphyrin ring in which an
iron (Fe) atom resides at its center, and can reversibly bind to oxygen. A normal adult
human contains six different species of hemoglobins. Each share a similar principle
function and structure, where hemoglobin-A makes up 92% of the total hemoglobin
concentration. To date close to 200 structural variants of hemoglobin are known, where
abnormal hemoglobin often has different oxygen binding relative to hemoglobin A.
Hemoglobin binds up to four oxygen molecules. The nature of oxygen binding onto
hemoglobin is cooperative (or allosteric), where the oxygen binding affinity to
hemoglobin depends upon the existing bound oxygen. The release of oxygen from
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hemoglobin in microvessels is controlled by many factors (pO2, pH, temperature,
concentration of carbon dioxide)[134]. A simplified mathematical form describing the
binding kinetics is described by Hill’s equation[134, 135].
SaO2

( pO2 P50 ) n
[1  ( pO2 P50 )]

In the equation above, the oxygen saturation index (SaO2) refers to the fraction of
oxygen molecular bound to hemoglobin, e.g., the fraction of oxygen ‘receptors’
occupied in a volume of blood. The pO2 or oxygen partial pressure defines the oxygen
concentration; the P50 is the oxygen partial pressure at 50% of oxygen saturation; n is
the Hill coefficient and describes the affinity of oxygen binding to hemoglobin.
Intravessel pO2 is often estimated by Hill’s equation when SaO2 is known. Taken
together, the SaO2, pO2, blood perfusion, and microvessel diameter are four major
factors influencing the local availability of oxygen at any time in the micro vasculature.

From this equation, the release of oxygen (reverse binding to hemoglobin) occurs when
blood plasma and tissue pO2 are relatively lower. Gas exchange from the vessel
compartment to the interstitial space takes place through oxygen diffusion and fluid
transport mechanisms. For diffusion, the oxygen partial pressure (pO2) gradient, the
endothelial permeability to oxygen, and the blood vessel’s surface area all contribute to
the amount of oxygen diffused from microvessels to the tissue space. For fluid transport,
the fluid exchange (Starling-Landis equation) due to differences in the hydrostatic and
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osmotic pressures across the endothelium barrier of the blood vessels can carry the
dissolved gases into the interstitial spaces. However, the second mechanism is
commonly ignored because the amount of dissolved oxygen in plasma is significantly
less than the oxygen released from hemoglobin. 50 years later, Duling and Berne
provided the first systematic measurements of pO2 using microelectrodes to test
Krogh’s model. They found a progressive longitudinal decline in perivascular pO2 in
arterioles proceeding capillaries as well as the capillaries [136-138]. Like any scientific
investigation, their finding evoked more questions, for example why oxygen exchange
occur in arterioles when oxygen exchange in capillary complex is adequate to provide
oxygen and nutrients to surrounding tissue. This highlights the technical challenges in
measuring key factors of oxygen transport. Contemporary thought accepted by the
majority of researchers in the field of oxygen transport states that the oxygen diffusion
pathway can occur between all three types of microvessels to the surrounding tissue
and between any two types of microvessel segments (see figure 1.3.8.1). The regulation
of local oxygen concentration from all possible diffusion and convection pathways and
the physiological role of each pathway remain under investigation (figure 1.3.8.1).
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Figure 1.3.8.1 Schematic diagram of oxygen transport via diffusion/convection in
terminal microvasculature(arterioles, capillaries, and venules)[139]. (Reprint permitted)

Finally, the rate of oxygen consumption of the tissue has a significant impact the oxygen
gradient within the parenchyma and oxygen transportation rate from blood. Oxygen
transport is a balance between the supply and demand of oxygen and nutrients, where
the mitochondria consume most of the oxygen in the cells. In order to acquire the
oxygen from blood, an oxygen tension gradient must exist between the vascular space
and parenchyma tissue. Direct oxygen consumption (VO2) can be measured by
phosphorescence quenching microscopy (PQM, see Chapter 3) and the local rate of
d(pO2)/dt quantified to determine VO2 [140].

Overall, the principles behind oxygen transport within the microcirculation system is
known (hemodynamics, physiology, diffusion lengths, metabolism rates), while the roles
of many known proteins and regulatory mechanisms in oxygen transportation remain
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unanswered (e.g., growth factors, cytokines, glutamine). Other areas of research in the
field of oxygen transport remain under investigation, such as (i) the role microvessel
structure in dictating the heterogeneous interstitial pO2 profile; (ii) the contribution to
the local tissue pO2 by the arteriole network relative to the capillary network; and (iii)
the importance of oxygen demand as modeled by Michael-Mentor kinetics and the
impact on microcirculation. To address these challenges and many others in oxygen
transport research, a look back in history demonstrates the importance of new and
innovative diagnostic technologies and methods. For example, in 1628, William Harvey
provided definite evidence that blood circulates within the body, but he did not know
how the blood flowed from the artery to the vein and could not answer how gases and
nutrients were delivered to the tissue. Harvey proposed the arterial blood poured into
the flesh as into a “sponge” and find its way back to veins. It was over 30 years later, in
1661, when Marcello Malpigh used a microscope to discover the existence of capillaries
within the lung of a frog, but he remained uncertain on the function of his great
discovery. It took another 200 years until physiologists, such as Ernest Starley, August
Krogh, and Eugene Landis, to understand the importance of the capillaries. Today thanks
to technology, a clear understanding of the hierarchical structure of the micovasculature
or lack thereof exists, but a complete understanding on the interplay between the
microcirculation, oxygen transport and usage is lacking and requires more research. The
ability to simultaneously measure and quantify pO2, hemoglobin status, and vascular
physiology are the key to answering the above questions [141, 142].
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1.5

A 3-D in vivo Assay of Hypoxia

Hypoxia has been shown to significantly impact clinical outcome, and its spatialtemporal variations can promote therapeutic resistance and metastasis. The Gold
Standard method to measure oxygen concentrations is highly invasive, either through
the use of needle-based probes or biopsy samples, and impractical. In vivo imaging
methods, such as MRI or PET/SPECT, remain unavailable for clinical use or the lack
temporal and spatial fidelity to characterize intra-tumor hypoxia. Other surrogate
markers by themselves provide an incomplete picture. To enhance our understanding of
hypoxia and in therapeutic interventions, a 3-D in vivo assay measuring intra-tumor
oxygen concentrations is proposed. The long-term objective of this research is to
characterize local regions within a tumor as diffusion- versus perfusion-based hypoxia,
as acute versus chronic hypoxia, anemic-based, or as influenced by other
microenvironmental features (interstitial hypertension, necrotic regions and transitional
regions of necrosis, etc.). As a first step toward achieving these goals, a biophysical
model is employed to fuse parametric maps of a tumor’s physiological hemodynamics
on a voxel-by-voxel basis. This assay will provide a multi-variable (multi-parametric)
approach to quantifying oxygen concentrations, and thus provides a means to better
differentiate the influence of therapeutic targets and protocols. Ultimately, this assay
will be combined with immunohistochemistry (IHC) images to provide an advanced
causal analysis linking the hypoxic microenvironment to biomolecular mechanisms while
undergoing therapy, thus bridging the gap between bench top discoveries and clinical
realization through the use of image-guided therapy.
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Experimental methods to study oxygen transport are discussed at two different scales:
(1) microscopic resolution in which optical techniques are the dominant approach to
characterize vessel structure/functional properties in Pm resolution, and (2)
macroscopic resolution in which different in vivo imaging techniques are used (MRI, CT,
PET). The microscopic measurement is a powerful tool capable of providing insight on
the action of oxygen transport mechanism, but severely limited in its clinical use. In vivo
imaging techniques cannot offer resolution afforded by microscopic techniques but are
capable of monitoring the noninvasively vessel and tissue function over a tumor volume.
Therefore, this study aims to develop a multivariate biophysical oxygen transport model
which estimates oxygen status with structural and hemodynamic inputs (such as
fraction of vessel volume and blood flow) acquired from contrast-enhanced imaging
modality and photoacoustic spectroscopy and fuses this information to determine local
oxygen concentrations (pO2) (Chapter 3). To validate this fusion-based model dubbed
MPO2, hemodynamic data and models obtained from the literature (GPO2) were
compared to the accuracy, precision, and quantification of the MPO2 model, where
scanner resolution and noise were simulated (Chapter 4). Next, MPO2 model was
applied to in vivo preclinical tumor data and compared to OxyLite probe measurements
of pO2 (Chapter 5), and finally to a therapeutic study where pancreatic xenograft
tumors were treated with the ant-angiogenic monoclonal antibody DC101 (VEGFR2
inhibitor) (Chapter 6). The results from these studies are discussed in Chapter 7, and
future studies proposed.
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CHAPTER 2.

SPECIFIC AIMS

Hypoxia, and the etiology of hypoxia, can infer metastasis and therapeutic resistance in
cancer patients. A key factor influencing the delivery of oxygen is the vasculature
formed during tumor angiogenesis. Over the past three decades, drugs targeting
angiogenic pathways have been developed, but with little or no success in improving the
overall survival in patients. Application of anti-angiogenic therapy (AAT) has been shown
to increase hypoxia and antagonize traditional cytotoxic therapies, such as radiation
therapy and chemotherapies. Recent studies also demonstrate a decrease in hypoxia
(increase in radiation therapy and chemotherapy) after the application of antiangiogenic drugs. Given the varied response of these drugs on tumor oxygenation,
diagnostic methods can provide valuable information to diagnose and guide therapy. A
number of techniques have been reported to image hypoxia (or pO2) or a feature or two
associated with hypoxia; however, these methods lack the ability to measure the
underlying vascular physiology and hemodynamics leading to hypoxia with the
necessary spatial-temporal fidelity. To investigate the role of hypoxia and oxidative
stress in cancer biology and therapy, a novel in vivo 3-D oxygenation assay that
quantifies oxygen concentrations and provides maps of tumor hypoxia maps within a
tumor.
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The method combines two key components: (1) the ability to measure the local
microvascular physiological hemodynamics using functional and molecular imaging
modalities, such as Dynamic Contrast-Enhanced Computed Tomography (DCE-CT) and
Photoacoustic Computed Tomographic Spectroscopy (PCT-S); and (2) the development
of a biophysical oxygen transport model that fuses the multiple parametric maps
obtained from functional and molecular imaging to calculate local pO2. Once these
models have been validated, they will be tested under different anti-angiogenic regimes
to anticipate tumor oxygenation and response to radiation therapy. To accomplish these
objectives, we propose to:

Specific Aim 1: Develop and simulate the pO2 distribution in normal tissue and tumor at
microscopic and macroscopic level, and evaluate the influence of spatial resolution and
noise on the accuracy and precision of pO2.

The goal of this specific aim is to determine the most accurate and precise mathematical
model of oxygen transport in normal and abnormal tissue. This model and the
corresponding measurements have a dependency on the spatial resolution (voxel size)
and signal-to-noise (sensitivity) of the imaging modality. First, tumor and brain tissue
vasculature, both vascular structure and function, are artificially generated based on
microscopy measurements obtained from the literature, and pO2 distributions
calculated based on Green’s solution to oxygen transport equations (Gold Standard or
control). Second, imaging maps of perfusion, fractional plasma volume, fractional
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interstitial volume, oxygen saturation, and hemoglobin concentration are formed at
different voxel sizes (spatial resolution). Third, a modified Krogh cylindrical model is
used to fuse the imaging information to obtain pO2 maps within these tissues. The
voxel-based pO2 values are compared between the microscopic solution using Green
function solution (GPO2) and the image-based multivariate Krogh cylindrical model
(MPO2). The accuracy and precision of these pO2 calculations based on measurement
errors and spatial resolution are assessed.

Specific Aim 2: Compare in vivo imaging of tumor vascular physiology and
hemodynamics to Oxylite probe measurements of pO2.

The goal is to perform PCT-S and DCE-CT imaging in a mouse model of cancer, acquire
OxyLite probe measurements of pO2, and compare the measured pO2 values to
calculated value for different voxel-based mathematical models. Breast tumors (MCF-7,
MCF-7VEGF, MDA-MB-231) growing in the mammary fat pads of athymic nude mice will
be imaged to obtain tumor physiology (F, PS, fp, fis) and hemoglobin status (CtHb, SaO2).
Immediately after scanning, the OxyLite probe will be used to measure local pO2 levels
in the tumor along a central axis of the tumor. These measurements will be compared to
in vivo data and MPO2 results.

Specific Aim 3: Assess the predictive capability of the in vivo 3-D assay in combined antiangiogenic therapy and radiation therapy.
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The objective of this specific aim is to analyze therapeutic data of mice receiving both
anti-angiogenic therapy and radiation therapy. Two cohorts of mice with pancreatic
(BxPC-3) tumors will be treated with low and high doses of an anti-angiogenic drug,
DC101. One-week post AAT, these tumors will be treated with 5Gy of X-ray radiation.
These tumors will be imaged using DCE-CT and PCT-S, and the voxel-based
mathematical model (MPO2) will be employed to calculate the pO2 maps prior to AAT
and prior to RT. These maps will be compared to the tumor volume response curves to
ascertain the radiosensitivity of the tumors, and if MPO2 assay is consistent with
therapeutic response.
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CHAPTER 3.

TUMOR MICROVESSEL STRUCTURE AND FUNCTION AND ASSOCIATED
MATHEMATICAL MODELS OF OXYGEN TRANSPORT

The purpose of this study is to develop a multivariate mathematical model to estimate
local pO2 (MPO2 method) in a finite volume voxel. To verify this model, a reference or
control is required. This reference utilizes microscopic data obtained from the literature
(Section 3.1) and a Green’s function algorithm to solve the set of coupled ordinary
differential equations (ODE) of oxygen transport to obtain microscopic levels of pO2,
which was shown to correlate with measurement (Section 3.2.1). Next, this same
information was used to simulated in vivo image data that was used to test the MPO2
model (Section 3.2.2). In this chapter, an overview on the how the detailed
microvascular structure and functional data was acquired by various optical techniques
is discussed. Next, the use of microelectrodes to quantify pO2 (Gold Standard) and
validation of Green’s function algorithm is presented. Finally, simulated parametric
images of vascular physiology and hemodynamics are presented and the MPO2 model
derived. The development of these techniques is used to investigate the specific aims
outlined in Chapter 2.
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3.1

Vascular Structure of the Reference Tissues and its Function

3.1.1 Window Chamber Animal Model for 3D Optical Tumor Vessel Imaging
Window chamber models and tumor transplants of SCID mice are two animal models
often used to study the microvascular structure and microcirculatory function in tissue
and tumors (see figure 3.1.1) [143-146]. These models provide real-time observations
over time of the microvessel structure and function in living animals using optical
techniques (e.g., intravital, confocal and two-photon microscopy), such as a vessel’s
segment length, diameter, and branching angle. When combined with fluorescence
microscopy and phosphorescence quenching, functional data including blood flow, pO2
and pH can be obtained [147-149]. However, window chamber models have a number
of disadvantages, such as they are technically difficult to perform and maintain, requires
specialized microsurgical skills and animal housing, and limits in the size of the tumors
(<3 mm in diameter and <500 Pm in thickness), which raises the question of whether
they accurately represent oxygen transport in large tumors. Therefore, subcutaneous or
orthotropic animal models provide a more realistic model to study oxygen transport
mechanisms in large solid tumors; however, other methods beyond optical imaging
must be developed.
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unable to clearly demark microvessel segments and provide hemodynamic information
[149]. Similarly, micro-CT provides excellent spatial resolution of the microvascular
structure within a tumor but can only done ex vivo [156, 157].

The blood flow data with an individual blood vessel are obtained from labs that
implement dual slit method and/or fluorescence-labeled RBCs. The dual slit method
[158, 159] utilizes a cross-correlation technique to calculate the time-of-flight between
video frames, where the traveling distance of a RBC is determined within two slits on
the screen. The RBC velocity is equal to the ratio of the distance the RBC traveled (two
slits) and the corresponding time-of-flight. This method also quantifies the local
hematocrit by measuring the diameter of each vessel segment (total vascular volume).
An alternative method to measure blood flow within an individual vessel segment is to
use fluorescently labeled RBC [160, 161]. Approximately 0.5 to 1.0% of RBCs withdrawn
from a donor animal is fluorescently labeled and inject back into the animal. RBC
velocity is measured by determining the time-of-flight of individual RBC using video
microscopy, and the RBC flux is measured by counting the number of fluorescently
labeled cells that pass through a microvessel as a function of time. The hematocrit can
also be determined if vessel diameter and RBD size are measured. The reason for
determining the RBC flux (or blood perfusion) is that it is related to the intravascular pO2
and not the RBC velocity [147]. The disadvantage of fluorescently labeled RBC method
includes the extensive video microscopy image analysis to obtain the desired
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parameters. Both methods require anesthesia to the animals which could significantly
reduce hemodynamics [162].

Table 3.1.2.1: Methods to study detailed microcirculation structure and
hemodynamics[95].
Microvascular Geometry
Method
Endpoint
Confocal/two-photons
Vessel orientation/density
microscopy
Contrast-enhanced
Vessel orientation/density
micro-CT

Magnetic resonance
microscopy

Vessel orientation/density

Microvascular hemodynamics
Method
Endpoint
Dual slit photometry
RBC velocity; blood flow
rate; flow direction
Fluorescent-labeled RBC

RBC velocity; blood flow
rate; flow direction; RBC
flux; hematocrit

Advantage
Full 3-D orientation

Disadvantage
Laborious; limited ROI

Full 3-D orientation

No concomitant
functional data;
laborious to inject
Microfill contrast agent;
ex vivo only
No concomitant
functional data; limit on
voxle size ~ 50 Pm;
weak sensitivity; issue
of high magnetic field

Full 3-D orientation

Advantage
Automated; real time
data, not technical
difficult
All micro-hemodynamic
parameters are
obtainable

Disadvantage
Cannot get hematocrit
and red cell flux
Not real time; need
playback tape; time
consuming

3.1.3 Intravascular pO2 Determination (PQM and Microelectrode Method)
In this section, two popular methods used to quantify the intravascular pO2 with
micrometer resolution are phosphorescence quenching microscopy (PQM) and oxygensensitive microelectrodes. Phosphorescence quenching microscopy or PQM was
developed by Wilson and his colleagues to measure the local pO2 in vivo implementing a
phosphor probe [163-165]. The phosphor is excited by a brief pulse of light in a finite
volume close to 10 Pm in diameter, and then decays to its ground state by emitting a

46
photon (phosphorescence) or transferring energy to a nearby oxygen molecule
(collisional quenching). The phosphorescence decay is a linear function of oxygen
concentration: K = K0 + Kq * pO2 (Stern-Volmer equation), where K is the
phosphorescence decay constant, K0 is the rate constant in the absence of oxygen, and
Kq is the quench constant. Both K0 and Kq are temperature and pH sensitive (see figure
3.1.3.1-A). The microscope optics remain at the same location over a period of time in
order to acquire an intensity decay curve (see figure 3.1.3.1-B), and from the
phosphorescence lifetime and intensity, oxygen concentration can be determined [166].
In a typical intravascular pO2 measurement, palladium-mesotetra-(4-carboxyphenyl)porphyrin (Porphyrin Products, Logan, UT) is injected into the blood stream and binds to
albumin or polytheylene glycol, thus remaining in the circulation. This method produces
accurate measurement at low pO2 but becomes unreliable if the pO2 exceeds 50 mmHg.
Leaking of Porphyrin from blood to surrounding tissue (e.g., tumor) after long circulation
contributes has been shown to increase the measurement error.
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(A)

(B)

Figure 3.1.3.1.A-B: (A) Schematic illustration of Phosphorescence Quenching
Microscopy[167]. (B) A typical example of a digitized phosphorescence decay curve
measured in the interstitial space of rat cremaster muscle, the decay constant is
extrapolated from the decay curve[167]. (Reprint permitted)

An alternative method is the use of oxygen microelectrodes. This technique is based
upon the electrochemical reduction of intravascular pO2 and also provides micrometer
resolution [168-170]. The electrodes are placed on the tip of needle and inserted into
the tissue. This can potentially damage the tissue and perturb the local oxygen status.
This becomes significant if the probe penetrates the vessel wall in order to measure the
intravascular pO2 or when the probe affects or hinders blood flow and RBC flux. Another
concern is the oxygen consumption from the probe itself (10-6 PL /min), which alters the
local oxygen concentration during the measurement. Guidance or visualization of the
probe in the tissue to verity the position inside vessels is often recommended.
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3.1.4 Interstitial Tissue pO2 Determination (PQM and Microelectrode Method)
Interstitial tissue pO2 measurement can be carried out by oxygen microelectrodes or
modified PQM method with specific Oxyphor probes. The modified PQM method
developed by Wilson et al integrates an 635 nm excitation light guide (1 mm in diameter)
and a second light guide used to collect 695 nm emissions (4 mm in diameter). The
probes are positioned against the surface of skin (by drawing a grid on the skin) (figure
3.1.4.1-B). The excitation light diffuses through the tissue and stimulates
phosphorescence of phosphor probe (R2 or G2 probes; i.v. injected). The emitted
phosphorescence diffuses through from the tissue to the location where collection
guide is placed and is measured. The contribution of final pO2 measurement comes from
the “banana-shaped” region from phosphorescence excitation optical fiber to collection
optical fiber (figure 3.1.4.1-A). The “tissue pO2” is the average pO2 from intracellular,
interstitial, and nearby intravascular compartments along the light path [171, 172]. This
method assumes the tissue pO2 is the main contributor to the measurement; however
the authors could not provide definitive evidence to justify their claim. Additionally the
spatial resolution of tissue pO2 is poor considering large diameter guides are used in
experiment. Thus the pO2 measurement by microelectrodes is clearly more accurate but
it is laborious. Hence depending upon the tumor size microelectrode method might not
be a practical choice to profile interstitial pO2 in entire tumor.
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To obtain both structural and hemodynamic information, the data compiled from all of
the above techniques were obtained from the literature and used in our simulations.
The measurements have been adapted by several groups to study or to simulate the
microvasculature behaviors or oxygen level in various organs[149, 178]. In the next
section, the mathematical models used to simulate the pO2 distribution in tissue are
discussed, where these measurements are used as input parameters. In Table 3.2.1, the
vascular structure parameters and hemodynamic values obtain from these studies are
listed.

3.2

Mathematical Models of Oxygen Transport

As previously described, the interplay between theoretical models and experimental
data, in particular in vivo imaging, has greatly enhanced our understanding of oxygen
transport and the impact on therapeutics. With recent advances in in vivo micro imaging
modalities (preclinical imaging), the concept of 3-D in vivo assay that combines
mathematical modeling and high-resolution functional and molecular imaging to map
oxygen levels and characterize tumor hypoxia can be realized. To test the feasibility and
identify potential limitations, biophysics models and computation models are employed
at the microscopic level, on the order of 1-10 Pm and compared to the macroscopic
level, on the order of 50-300 Pm. For the former, a combination of confocal imaging and
Green’s function algorithm (GPO2-model) is used to calculate the oxygen level at the 10
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thus the tissue pO2 can be estimated by an ideal cylindrical vessel model. This
assumption is adequate for the skeletal muscle, where the capillaries run parallel to
muscle fibers. However, in other organs, this assumption is no longer valid. Clearly, an
oxygen transport model must consider the complexity of the vessel network topology.
To deal with this complexity, Hsu and Secomb developed an approach where each
vessel is represented as a distribution of oxygen sources within a defined tissue region.
The local oxygen concentration is the sum of the pO2 from those sources. There are
several key assumptions in Green’s function method: (1) the entire system is in a
thermodynamically static state, (2) oxygen solubility and diffusion constants are
homogeneous and isotropic, (3) myoglobin assisted oxygen transport is ignored, (4) a
linear relationship between oxygen concentration and pO2 in tissue is assumed (Henry’s
gas law), (5) a nonlinear relationship exists between pO2 and oxygen consumption rate
in tissue as defined by the Michaelis-Menten equation, (6) the cooperative binding of
oxygen to hemoglobin exists as defined by Hill’s equation, and (7) the transient pO2
exchange between the RBCs and plasma is replaced by an average pO2 (Pb) in vessel
lumen. The impact of these assumptions is discussed.

Two coordinate systems are used in formulating the mathematical equations in tissue
and in blood vessel (figure 3.2.1.1). A Cartesian coordinate system(x1, x2, x3) is used to
describe the tissue space, the oxygen concentration in tissue space is denoted by

Ct (x1,x2,x3) or Pt (x1,x2,x3) which satisfies
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D 2Ct

M ( Pt ) or DD 2 Pt

M ( Pt )

(1)

where D is the oxygen diffusivity,  denotes the Laplacian, and M ( Pt ) is the local
metabolic rate. Note that the oxygen concentration is linearly related to oxygen partial
pressure Ct

D Pt where D is oxygen solubility in tissue. In the vessel compartment,

the oxygen reserve is the sum of bound oxygen and dissolved oxygen. Under normal
conditions, the dissolved oxygen is much less than bound oxygen and is neglected.
Therefore, the total available oxygen in blood is

Cb

(2)

HC0 S ( Pb )

S ( Pb )

Pbn ( Pbn  P50n )

(3)

where H is hematocrit, C0 is the fully saturated hemoglobin concentration, S ( Pb ) is
hemoglobin saturation, and Pb is the intravascular oxygen partial pressure. Notice that
equation (3) is Hill’s equation, and describes the cooperative binding of oxygen to
hemoglobin. The rate of oxygen efflux per unit length along a vessel segment is denoted
by q(z). The conservation of mass implies that

F dCb dz q( z )

(4)

where F is the blood flow. The efflux is calculated by integrating around the radius of
the vessel segment, r0 :
2S

q ( z )  DD ³ r0 (
0

wPb
)dT
wr
.
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source, similar to the electrons within an electric potential (or circuit). According to
potential theory [180], the Green’s function G(x;x*) is defined as the tissue pO2 at a
point x=(x1,x2,x3) resulting from a unit point source at x*,

G ( x  x*)  1/ V ,

 2G

(7)

where G represents the three-dimensional Dirac delta function and V is the entire tissue
region volume. Since equation (1) is linear and Green’s function is additive, Green’s
function can be decomposed into G
point source (  2G1
(  2G2

1 V ) ( G2

G1  G2 , where G1 1 | x  x* | is the solution for

G ( x  x*) ) and G2 is the solution for the constant term 1/V

c1 x1  c2 x2  c3 x3  d1 x12  d 2 x22  d3 x32 ). The coefficients are

determined by setting G

G1  G2 and applying setting the net diffusive flux across

each of the six boundary planes to zero,

w
(G1  G2 )dS
wn
All surfaces

³

Given the kernel function G

(8)

0
.

G1  G2 , Green’s function solution to equation (7) is

pO 2 x1, x 2, x3

³

G ( x, x*)q ( x*)dx *

(9)

sources

where q ( x*) is the source distribution which includes positive source (oxygen supply)
and negative source (oxygen sink).

Numerical Solution to Green’s Function Algorithm. Blood vessels are discretized into m
short segments and the tissue space is discretized into n small cubic regions. For the
simulations performed in the specific aims, the distance between the centers of these

56
cubic regions is 15 Pm. According to equation (9), the average pO2 at the blood-tissue
interface of segment i and in tissue region i are

Pb ,i

m

n

j 1

j 1

¦ Gijbb q j  ¦ GijbtM j for i 1,..., m

(10)

and

Pt ,i

m

n

j 1

j 1

¦ Gijtb q j  ¦ GijttM j

for i 1,..., n ,

(11)

where q j represents the source strength of segment j and M j represents the (negative)
source strength in tissue region j .
Pb,i

Pc,i  Kqi

for i 1,..., m

(12)

where Pc ,i is the intravessel pO2 at the midpoint of segment i. The oxygen consumption

M j is represented by the Michaelis-Menten equation,

Mj

M 0

Pt , j
( P50  Pt , j )

for j 1,..., n ,

(13)

where M 0 is the maximum oxygen consumption rate; P50 is the pO2 at half of
maximum consumption rate M0. To find Pc ,i , equation (4) is integrated. It is calculated
based on the rate of oxygen transport due to convective forces along the length of the
vessel segment relative to its midpoint f ( Pc ,i ) , which can be expressed as a linear
function of source strength q j .
m

f ( Pc ,i )

f ( Pc0,i )  ¦ V i , j q j
j 1

(14)
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Pc ,i

m

f ( f ( P )  ¦ V i, j q j )
1

0
c ,i

(15)

j 1

Here, Pc0,i is the intravascular pO2 of segment i in the absence of diffusive oxygen
exchange, that is q j = 0 for all j . For a series of segments forming a vessel without
branches, V i , j is equal 1 if segment j is upstream of segment I, 0 if segment j is
downstream of segment I, and 0.5 when i = j. By combining equations (10), (12), and
(15), the following nonlinear equation is used to determine pO2 at each grid point:
m

m

j 1

j 1

¦ Gijbb q j  f 1 ( f ( Pc0,i )  ¦ V i, j q j )  Kqi

n

¦ GijbtM j for i 1,..., m
j 1

(16)
.

Initial estimates of tissue oxygen levels and vessel source strength are first defined, and
tissue oxygen strength M j was calculated by using equation (13). The left hand side
equations are solved together with net oxygen delivery equal to consumption equation
m

n

j 1

j 1

( ¦ q j  ¦M j

0 ) by biconjugate gradients stabilized method [181], giving updated

values for qi . The procedure is repeated using the updated values until convergence to
a specific criterion is reached. Equation (11) with updated Mi and qi is used to calculate
tissue pO2. This procedure is also repeated after receiving updated vessel pO2, Mi , and

qi until convergence is reached.

Description Of 3D Microvasculature Data Source. In this study, the correlation of Green’s
function pO2 (GPO2) to the multivariate modified Krogh pO2 (MPO2) is evaluated within
the brain (reference tissue) (0.15mm x 0.16mm x 0.14mm) and a tumor (1mm x 1mm x
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0.15mm). Both structural and rheological data was obtained for each individual
segment as reported by Dewhirst et al
(http://www.physiology.arizona.edu/people/secomb/network) and Fonteanella et al [94,
161]. Briefly, each individual vessel segment in the network was represented by an ideal
cylinder, where the diameter was assumed to be uniform and the blood flow and
hematocrit (Hct) remained constant.

3.2.2 MPO2 Method to Calculate Tissue pO2
Derivation of the MPO2 Model. The multivariate single vessel oxygen transport model,
or the modified Krogh oxygenation model, shares many assumptions and governing
principles with Green’s function algorithm [135]. For example, the oxygen distribution in
the tumor is dominated by diffusion; therefore, the oxygen partial pressure pO2T
satisfies (see equation (1))
D  2 pO2T

H M pO2T

where M (y) =

M0 y
p0  y ,

where D is the oxygen diffusion constant, H is Henry’s constant, and M is the tissue
oxygen consumption rate, which follows Michaelis-Menton kinetics (M0 is the maximum
oxygen consumption constant and p0 is the pO2 at half-maximal consumption constant).
For a single cylindrical vessel placed at the center of the voxel, the above equation can
be written in cylindrical coordinate as
ª 1 w § wpO2T
D «
¨r
¬ r wr © wr

·º
¸»
¹¼

H M pO2T

(17)
,

59
where r is the radial distance from the center of cylinder and z is the vessel length. Note,
this solution ignores the second derivative with respect to z.

Within the blood vessel, the bound oxygen is released based on the plasma pO2 based
on the hemoglobin dissociation curve. Thus the dissolved oxygen concentration in
plasma, C r , z , is formulated as function of diffusion process ( D) , blood flow ( F ) , and
oxygen released from hemoglobin,

wC
F
wz

ª 1 w § wC · w 2C º
D «
¨r
¸ 2 » R
¬ r wr © wr ¹ wz ¼
.

Here R is the deoxygenated hemoglobin production rate, which is proportional to the
dissolved oxygen concentration in plasma. The saturated hemoglobin concentration

C c r , z bound to the hemoglobin within the RBCs is represented by the following
equation:

F

wC c
wz

Rc
,

where R’ is the oxygenated hemoglobin production rate (Hill’s equation). These two
differential equations can be combined to form

F (1  m)

wpO2B
wz

ª 1 w § wpO2B · º
D «
¨r
¸ » where m
¬ r wr © wr ¹ ¼

n P50n H Osat

( pO2B ) n 1
P50n  ( pO2B ) n

where pO2B is the oxygen partial pressure in blood, Osat is the saturated hemoglobin
concentration, n is the average oxygen bound to hemoglobin, and P50n is the partial

2

,
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oxygen pressure when the oxygen saturation(SaO2) is equal to 50%. At the boundary
between the vessel wall and tissue, the oxygen partial pressure and its first derivative
are required to be continuous.
B
2

pO

wpO2B
pO =pO2 and
wr
T
2

wpO2T
wr

wpO2
; at r
wr

rc

Therefore, the final expression for the pO2 is

pO2 (r , z )

pO2 ( z )

2
§r·
rc2 M H ª § r · º rT2 M H
«1  ¨ ¸ » 
ln ¨ ¸
pO2 ( z ) 
4 D « © rc ¹ »
2D
© rc ¹
¬
¼

pO2 ( z

2
º
M H ª§ rT ·
«¨ ¸  1» z
0) 
1  m F «© rc ¹
»¼
¬

(18)

(19)

In principle, the initial pO2 value is evaluated from SaO2 which can be measured by PCTS. All simulation parameters of MPO2 model are listed in table 3.2.2.1.
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Table 3.2.2.1 Simulation parameters used in MPO2
Parameter
Value

References

Oxygen consumption rate, M 0

30 P L g .min

[182]

Blood flow rate, F ,in sensitivity
analysis

0.15 mL g .min

In-house DCE-CT
data

Hct

0.4

Vessel radius rc in sensitivity
analysis
Saturated hemoglobin
concentration C '

5 Pm

[182]

8800 PM

[134]

CtHb-PCT([Hb] from PCT-S)

3.0 g/dL

In-house PCT-S data

P50

26 mmHg

[134]

n

3.0

Henry’s constant, H

0.74 mmHg P M

[135]

Oxygen diffusion constant D

2000 P m 2 sec

[183]

Oxygen solubility in blood

0.0385 P l g .mmHg

[184]
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CHAPTER 4.

MPO2 PERFORMANCE AT VARIOUS VOXEL SIZES

In last chapter, the techniques used to acquire detailed microvasculature structure and
associated hemodynamics was discussed. The fundamental principle and
implementation of the Green’s function algorithm used to calculate the microscopic pO2
profile from the above data and of MPO2 model used to calculate the average pO2 in a
voxel were derived. This objective of this chapter is to evaluate the accuracy and
precision of the MPO2 model at various voxel sizes and noise levels for brain and tumor
tissue, where Green’s function pO2 (GPO2) was used as a reference.

4.1

MPO2 Validation Method Using Green’s Function as Standard
4.1.1 Implementation of a Virtual Voxel Grid

Prior to applying a virtual voxel-based grid, the pO2 distribution within the tumor and
brain tissue was calculated using the Green’s function algorithm (Chapter 3). The virtual
grid is composed of isotropic voxels interspersed within the entire tissue volume (see
figure 4.1.1.1 for 2D demonstration).
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Since the diameter, length, hematocrit (Hct), and blood flow of each vessel segment
were known, the fraction of vessel volume, hct, and effective blood flow simulating the
measurements made by dynamic contrast-enhanced imaging (e.g., DCE-CT) in each was
calculated and used as inputs to the MPO2 model to calculate the average pO2 in a voxel.
The standard (or reference) pO2 was the average of all pO2 levels at the microscopic
scale as determine by the GPO2 model. Therefore, the virtual grid allowed the
investigation of correlations between MPO2 and GPO2 with respect to voxel size. In
addition, the number of data points was increased by translating the voxel grid to
different locations (note, if a portion of the voxel lay outside of the tissue, it was
excluded from the analysis). In the tumor, six different voxel sizes were investigated: 50,
100, 150, 200, 250, and 300 Pm. In brain, 50 and 100 Pm voxel size was simulated owing
to the limited brain volume.
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4.1.5 The SaO2 and Initial pO2 in a Voxel
A Krogh model requires the initial pO2 as a determinant to calculate the pO2 distribution
around a cylindrical vessel. Most of Krogh type model simulation adapted a
physiological pO2 as the initial pO2 value and used it as a constant in modeling study.
Often the choice of initial pO2 varies among the publications. In this study, the
intravessel pO2 by Green’s function to be used to determine the SaO2 as measured from
in vivo imaging, which in turns, was used to determine the initial pO2. The latter was
used as one of the input arguments for MPO2 tissue oxygenation algorithm. The oxygen
saturation level within a vessel segment was derived from intravessel pO2 by inverting
Hill’s equation. The volume-weighted average SaO2 of the voxel was calculated with the
following formula:

¦ S xV
¦V
i

SaO2 (voxel )

i

i

i

i

th
Si is the SaO2 of the i vessel segment; Vi is the volume of the blood vessel inside a

voxel contributed from the ith vessel segment. The pO2 within a voxel was calculated
using the average SaO2 and inverting Hill’s equation; the initial pO2 at the voxel entrance
for MPO2 simulation was then set to be double of the voxel pO2. The rationale is as
follows:

pO2 ( z )

pO2 ( z

2
º
M H ª§ rT ·
«¨ ¸  1» z
0) 
1  m F «© rc ¹
»¼
¬

,
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Givent that this equation is linear along the z-axis (length of blood vessel), the
relationship between the average pO2 and input pO2 is

pO2 ( z )

pO2 ( z

2
º
M H ª§ rT ·
«¨ ¸  1» z
0) 
1  m F «© rc ¹
»¼
¬
,

which can be rewritten as
pO2

pO2 (0)  pO2 ( L)
2

or
pO2

pO2 (0)  pO2 ( L)

2  pO2 (0) 

M H
G2 (rc , rT )  L
(1  m) F

The second term on the right is a constant; therefore,
pO2 (0)

1  §¨ pO  M  H G (r , r )  L ·¸
2
2 c T
¸
2 ¨©
(1  m) F
¹

However, an exception occurs if pO2 is less than zero along the length of the blood
vessel. In these situation, negative values are set to zero and a recalculation of pO2(0) is
determined.
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4.1.6 Linear Regression to Evaluate the Correlation Between the GPO2 and MPO2
Models of pO2
A linear least squared method was used to fit the pO2 value as determined by the MPO2
and GPO2 models. A Pearson correlation coefficient was calculated to indicate the
degree of linearity between the paired pO2 values and the r-squared to determine the
goodness-of-fit. To increase the number of data points in the regression analysis, in
particular for the larger voxel sizes, and to better simulate tumor vascular physiology
heterogeneity, the maximum oxygen consumption rates was varied randomly (in +/-50%
range) relative to the initial value and the total tumor blood flow was chosen randomly
(in +/- 25%) relative to the initial value. In addition, the voxel grid was moved to
different regions within the tumor to simulate various vessel configurations in the voxels.

4.1.7 Sensitivity of MPO2 to Changes in the Vascular Inputs
MPO2 model considers several nonlinear relationships between two variables, including
Hill’s equation and Michaelis-Menton kinetics, when numerically calculating a voxel’s
pO2. Although the local pO2 is the synergistic consequence of vascular physiology and
microenvironment, some determinants will be more dominant than others in regulating
the local pO2 value. To compare the pO2 response among the key inputs of MPO2 (blood
perfusion, vessel radius, hemoglobin concentration, SaO2, and oxygen consumption
rate), a single variable was adjusted to +/- 10 and 20 percent relative to its reference
value while all other variables were held constant. The reference value of the blood
perfusion, the hemoglobin concentration, and the SaO2 were selected from in house
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preliminary tumor DCE-CT and PCT-S measurements and the oxygen metabolic rate was
chosen from publications. The percentage change in pO2 was calculated and plotted to
assess the sensitivity and relationship of each variable to the pO2.

4.1.8 MPO2 Uncertainty Analysis
All physical quantities are subject to uncertainties in their measurements. The MPO2
model simulated these uncertainties consistent with measurements acquired from in
vivo functional imaging modalities. In the analysis, several 150 Pm voxels were used to
test the precision and error in the pO2 from 5 to 25 mmHg range. A randomly generated
Gaussian error function was used to simulate the uncertainty in the fractional vessel
volume and blood perfusion in each voxel, where the full width at half maximum
(FWHM) of the Gaussian error function was 20% of the voxel’s nominal value. Ten
simulated blood perfusion measurements and the fraction of vessel volume
measurements were performed, and the corresponding pO2 based on MPO2 model
calculated. From these ten simulations, the average and standard deviation were used
to determine the accuracy and precision of MPO2.

4.2

Results of Vasculature Characterization

4.2.1 Brain and Tumor Microvasculature Characterization
The microvasculature structure and associated physiology are directly related to the
local delivery of oxygen within a tissue or organ. To test the feasibility of our in vivo 3-D
pO2 assay, the pO2 distributions (or images) using Green’s function method (GPO2)
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(reference) and the proposed multivariate fusion model (MPO2) for a rat brain (normal
control) and a tumor were compared, and the influence of the spatial resolution and
noise of the imaging system on the systematic and statistic uncertainties in pO2
investigated.

For these studies, the reconstructed microvascular networks of the brain (150 Pm x 160
Pm x 140 Pm) and tumor (990 Pm x 810 Pm x 150 Pm) as shown in Figure 4.2.1.1 A-B,
were modeled based on acquired data from a scanning confocal microscope [186]. In
Figure 4.2.1.2, the blood flow and diameter histogram of the brain and the tumor vessel
network is displayed. The minimum diameter of both the brain and the tumor
vasculature was close to 5 Pm, but the range of blood flows from the minimum vessel to
the largest showed a difference of a factor of 78 (0.5 nL/min against 0.0064 nL/min). 26
percent of the tumor vessel segments flow rates was less than 0.5 nL/min. In addition,
those vessel segments with low flow rates appeared in capillaries (diameter ~ 5 Pm) and
arterioles (diameter > 15 Pm). For normal microvessel networks, a linear correlation
exists between the vessel diameter and flow which is lost due to the abnormal
vasculature in the tumor (Figure 4.2.1.3).
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Figure 4.2.1.1.(A/B): Reconstructed microvessel network of tumor and brain by confocal
scanning microscope at sub-Pm resolution. The unit is Pm in both microvasculatures.
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Figure 4.2.1.2: Tumor and brain microvasculature diameter and flow histogram. Tumor
histograms are colored in blue; brain histograms in red. For tumor blood flow, the
number of vessel segments with flow rate < 5 nL/min is close to 400; the inset displays
the detail distribution of blood flow from 1 to 10 nL/min.
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Figure 4.2.1.3: Blood flow correlation of tumor microvasculature on left and of brain
vasculature on right.

4.2.2 The 3-D pO2 Map as Determined by Green’s Function Algorithm
The 3D pO2 distributions in the tumor and brain tissue based on GPO2 are displayed in
Figure 4.2.2.1. Note the spatial resolution of this data is 15 Pm.

(A)
(B)
Figure 4.2.2.1: (A) Partial oxygen pressure distribution (pO2) in tumor. The entire tumor
region is 990 Pm x 810 Pm x 150 Pm in 2D view. (B) pO2 in brain. The brain region is 150
Pm x 160 Pm x 140 Pm. The colorbars on the right indicate the pO2 value. The scale bar
in tumor represents 0.2mm; the scale bar in brain represents 0.1mm.
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4.3

Comparing the Results of MPO2 Model to GPO2 Standard

In section 4.1.1, the concept of a virtual grid was introduced to simulate the spatial
resolution of a parametric map obtained from a functional imaging (e.g., DCE-CT). First,
the average pO2 in a voxel based on the GPO2 model was calculated. Next, the vascular
physiology and hemodynamics in each voxel were calculated and inserted into
equations (18)-(19) to derive the corresponding pO2 based on the MPO2 model. In
Figure 4.3.1, an example of these maps (or images) of the vascular physiology, the
MPO2, and the GPO2 values for pO2 are displayed for 100 and 200 Pm voxel sizes.
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4.3.1 Characterization of MPO2 Distribution in a Single Voxel
MPO2 is a multivariate, single-vessel, modified Krogh model. Knowledge of the typical
pO2 profile obtained from this model can help assist and further explore the oxygen
transport mechanism in tissue, such as the causes to the accuracy and precision of this
technique. The typical 2D view of the pO2(r,z) distribution within a voxel from a single
vessel placed at its center is shown in Figure 4.3.1.1, where the blood flow was from left
to right. The cellular density, as determined from imaging (fcell=1-fBV-fis), in the tissue
region was assumed to be uniform. The partial oxygen pressure decreased
monotonically in radial and longitudinal orientation (Figure 4.3.1.1). The anoxic region,
where tissue pO2 was equal to zero, could exist at the remote corners, where oxygen
supply from vessel was weak.
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Figure 4.3.1.1: Two-dimensional pO2 profile demonstration by single vessel MPO2
model in a 200 Pm voxel. A single 20-Pm diameter vessel is placed at the center of a
(200 Pm)3 voxel. The origin of a cylindrical coordinate is located at the entrance of blood
vessel with z-axis oriented toward to blood flow direction. The cylindrical vessel
configuration leads to pO2 distribution symmetry in radial and azimuthal direction.
Anoxic region, pO2 = 0 mmHg, could occur at the remote corners in MPO2 modeling.
Any negative pO2 from MPO2 calculation is replaced by zero mmHg. Average tissue pO2
by MPO2 algorithm excludes the pO2 contribution from the vessel lumen. The unit of
gray color bar is mmHg.

4.3.2 MPO2 Sensitivity to Vascular Inputs
MPO2 integrates or fuses variables based on biophysical models where the measured
inputs are obtained from in vivo imaging. In this section, the sensitivity of pO2 on these
variables was simulated. Each variable in turn was modified by -20, -10, 0, +10, and +20
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percent relative to baseline values while holding all other parameters constant, and the
change in the pO2 value measured.

Displayed in Figure 4.3.2.1 is the percent error in the pO2 as a function of the blood
vessel radius, perfusion, metabolic rate, SaO2 and hemoglobin concentration. Based on
these results, each factor affected the pO2 values but in different ways. For example,
changes in the metabolic rate showed the highest impact to tissue oxygenation in -20%
group, while changes in the blood perfusion was dominant in 20% group. The oxygen
consumption rate had the largest impact on tissue pO2, where the average absolute
percent change in pO2 percentage was 16.0%. The hemoglobin status as determined by
SaO2 and CtHb resulted in a 12.6% and 15.0% variation in pO2, respectively, and the
physiological parameters such as the vessel diameter and blood perfusion changed the
pO2 by 9.7% and 15.2%, respectively.
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Figure 4.3.2.1: Partial oxygen pressure sensitivity of five MPO2 input parameters. The
pO2 response are organized into five groups (-20%, -10%, reference, 10%, and 20%). All
responses are in percentage and normalized with respect to the referenced determinant;
accordingly the response of the reference group is zero.

4.3.3 Linear Regression Results of MPO2 versus GPO2
A key objective of specific aim one is to validate the accuracy of the MPO2 at various
voxel sizes, at various scanner spatial resolutions. In figures 4.3.1.1 and 4.3.1.2, scatter
plots of the pO2 within each voxel for as determined by MPO2 and GPO2 were fit to a
line (linear regression analysis) for normal brain tissue and tumor as a function of voxel
size. For the rat brain tissue, both 50 and 100 Pm voxel sizes demonstrated a high level
of correlation with a slope of 1.0, an offset of less than 0.85 mmHg, and an Rsq of 0.86
and 0.91, respectively, and p-value less than 0.01. Similarly, the correlation between
MPO2 and GPO2 for the tumor was very good for voxel sizes of 100, 150, and 200 Pm,
where the slopes were 1.0, offsets within +/-1 mmHg, and Rsq values of 0.80, 0.83, and
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0.75, respectively with p-values less than 0.01. However, for small (50 Pm) and large
(250 and 300 Pm) voxel sizes, the quality of the fits decreased. The scatter plot for a 50
Pm voxel size had two outlier groups, one where the MPO2 overestimated the GPO2
values and another that underestimated these values (the short-dash and long-dash
oval curves, respectively). Even though the slope and offsets were reasonable, the
variance in the data was significantly larger (e.g., Rsq of 0.71) due to this systematic
affect. Unlike the 50Pm voxel data set, a decrease in the slope and increase in the offset
wass observed, with an increase in the variance (Rsq).
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Figure 4.3.3.1: Brain pO2 scattering plot of MPO2 and GPO2. Brain pO2 correlation plots
at voxel sizes 50 and 100 Pm are shown in the panel A and B. The abscissa consists of
the average Green’s function pO2 of the voxels; the ordinate consists of the MPO2 from
the same voxels. Red lines are the linear regression fitting; the result of linear regression
fitting and Rsq are displayed on top-left corner.
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Figure 4.3.3.2(A/F): Tumor pO2 correlation of MPO2 and GPO2 as function of the voxel
size. Six pO2 scattering plots of pO2 (mmHg) at voxel sizes (50, 100, 150, 200, 250, and
300 Pm) are displayed in the panel (A-F). At 50 Pm voxel size (panel A), the
underestimated MPO2 outliers are enclosed in a long dash oval; the overestimated
MPO2 grouped in short dash oval.
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4.3.4 The Nearest Neighbor Algorithm to Correct for 50-Pm Voxel Outliers
The underlying causes of the outliers were investigated. In figures 4.3.4.1.A-B, the
location of the overestimated (MPO2 >> GPO2) and the underestimated outliers (MPO2
<< GPO2) were identified. The overestimated outlier voxels were either located near
(not in voxel) a major arteriole or the fraction of the vessel volume was more than 0.8.
On the other hand, the underestimated voxels had a low fractional vessel volume and
the vessel density of the surrounding voxels was also very low. This observation
reflected the abnormal tumor vasculature heterogeneity. To improve the regression
analysis, a nearest neighbor algorithm was adopted to correct outliers by considering
the boundary conditions imposed by these voxels. The nearest neighbor algorithm
replaced the pO2 value in MPO2 model by the average pO2 from the nearest
surrounding neighbors. After applying this algorithm, the variance in the 50-Pm voxel
plots greatly improved (Figure 4.3.4.2-A) (see Appendix A for detailed explanation on
algorithm implementation), where the two outlier populations disappeared and the Rsq
improved from 0.71 to 0.81 (figure 4.3.4.2-B).
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4.3.5 MPO2 Uncertainty Analysis
Any physical measurement contains two essential components: (1) a value giving the
best estimate possible for the quantity measured, and (2) the degree of uncertainty
associated with this value. Since the MPO2 model is a function of measurements
acquired from imaging, simulations were performed to understand the influence of
error propagation of these measurements to the calculated pO2 value. These simulation
results are displayed in figure 4.3.5.1 and suggest that MPO2 showed that the average
coefficient of variation (CV) was 7% after adding in noise (20 percent) to the fractional
vascular volume and 3.4% for blood perfusion.
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Figure 4.3.5.1: Response of MPO2 to the perfusion measurement uncertainty (on left)
and the f-plasma measurement uncertainty (on right). Horizontal axis represents the
Green’s function pO2 of the voxel and vertical axis the average pO2 from 10 simulated
MPO2 with blood perfusion and fraction of vessel volume uncertainty following
Gaussian error function. The blue dot-dash line is the pO2 regression line of 150 Pm
voxel (see figure 4.3.3.2-C).
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CHAPTER 5.

COMPARING IN VIVO PO2 MEASUREMENTS BASED ON THE MPO2
MODEL AND OXYLITE OXYGEN SENSOR

In Chapter 4 (specific aim 1), a correlation was demonstrated between the local pO2
levels calculated using the modified Krogh model, MPO2 model, and Green’s function
algorithm, GPO2 model, which was based on the detailed microvascular structure and
functionality of tumor and brain tissue. In this chapter, an OxyLite oxygen sensor is used
as a Gold Standard to measure the local pO2 in a tumor. These measurements are
compared to the pO2 as determined from the MPO2 model, where the input parameters
to this model (the physiology of the tumor’s hemodynamics: perfusion, fractional
plasma volume, fractional interstitial volume, oxygen saturation, hemoglobin
concentration) are measured using DCE-CT and PCT-S. Thus, a direct comparison
between the theoretical and measured pO2 values, (MPO2) and OxyLite probe
respectively, is possible.

87
5.1

Introduction

The polarographic needle oxygen sensor, or Eppendorf probe, is an accurate method to
measure in vivo tissue pO2 (considered the Gold Standard). It is composed of two
electrodes, where the current generated by the electrochemical reaction at cathode (O2
+ 2H2O + 4e- Æ 4OH-) is proportional to the oxygen concentration [187]. Due to cost, it
is not widely used within clinical and basic research facilities. However, the OxyLite
oxygen sensor (Series-E, Oxford Optronix, Oxford, UK) provides an easy-to-use and low
cost alternative. It employs phosphorous quenching technique to quantify the local
oxygen concentration. Oxygen, as a triplet molecule, has the ability to efficiently
d e cr e a se the fluorescence and phosphorescence of certain luminophores, which is
called "collisional quenching"[188]. An LED emits a pulse of blue light (475 nm)
exciting a chemical complex at the tip of the probe, which subsequently emits photons
at 600 nm. When an oxygen molecule collides with the excited complex, the excess
energy will be transferred to the oxygen molecule, thus quenching the fluorescence
signal. The degree of quenching is directly related to the oxygen concentration or
partial pressure level of the oxygen-containing media [188, 189].

The OxyLite sensor has a number of advantages over the Eppendorf probe: (1) low cost
and flexible; (2) not based upon oxygen consumption [190]; (3) long-term pO2
measurement stability; (4) no electric hazard during measurement. Several studies have
shown close agreement between the pO2 measurements using the OxyLite probe and
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the polarographic needle oxygen sensor [86, 191], and thus used as the Gold Standard
technique to validate MPO2. First, OxyLite calibration data was obtained where the
dissociation curve -- SaO2 versus pO2 – was analyzed for ex vivo blood samples. Second,
the dissociation curves for breast tumors with differing angiogenic phenotypes were
investigated, where photoacoustic imaging was used to measure SaO2 levels. Finally,
the local pO2 levels calculated using MPO2 model and measured hemodynamic images
(DCE-CT and PCT-S) was compared to OxyLite measurements.

5.2

Material and Method

5.2.1 Calibration Phantom
A closed blood circulation system was constructed to validate or calibrate the OxyLite
oxygen sensor by measuring the oxygen saturation (SaO2) and partial oxygen pressure
(pO2) in recently expired blood. This blood phantom consisted of a tonomoter, a
capillary pump, a hot plate (maintain temperature), a set of flow gauges and a mixing
chamber (figure 5.2.1.1), and by controlling the flow rates of nitrogen and oxygen, the
amount of oxygen exposed to the blood within the tonometer was varied to obtain a
range of SaO2 and pO2 levels. The OxyLite probe (series E, temperature integrated) was
placed within the tonometer to monitor blood pO2, and after reaching a steady-state
level (2-3 minutes), a sample was drawn and the SaO2 measured using a cooximeter(682 co-oximeter, Instrumentation Lab). The plot of the SaO2 as a function of
pO2 was fit to Hill’s equation,
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SaO2

pO2

n

( P50  pO2 ) ,
n

to determine Hill’s coefficient, n, and the pO2 at the fifty percent SaO2 level, P50.

Figure 5.2.1.1: Experimental setup for blood phantom SaO2 and pO2 quantification with
various mixtures of air and Nitrogen.

5.2.2 Animal Models
Three 6-8 week old female athymic (nu/nu) mice (Harlan Sprague-Dawley, Indianapolis,
IN) were injected with 1-5x106 MCF-7, 1x106 MCF-7VEGF (stably transfected with the
VEGF165 gene) or MDA-MB-231 breast cancer cells in 0.1 mL of Hanks’ buffered saline
into the mammary fat pads. For mice implanted with MCF-7 cancer cells, an estradiol
pallet (0.72mg, 60 day formulation) was implanted using a sterial 14-gauge trocar 24
hours prior to tumor implantation in order to provide a supplemental release of
estrogen. Tumors were allowed to grow to an average diameter of 8-12mm prior to in
vivo imaging and Oxylite probe measurements. All animal preparation and procedures
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for this study were reviewed and approved by the Indiana University Institutional
Animal Care and Use Committee.

5.2.3 Imaging Protocols
Prior to Oxylite probe measurements, each mouse was imaged using dynamic contrastenhanced CT (DCE-CT) and photoacoustic CT spectroscopy (PCT-S) to determine vascular
physiology (perfusion, F; permeability surface-area product, PS; fractional plasma
volume, fp; and fractional interstitial volume, fis) and hemoglobin status (oxygen
saturation, SaO2; hemoglobin concentration, CtHb), respectively. While under
anesthesia (0.1 mg/kg (i.m.) acepromazine and 0.1 mg/kg (i.m.) torbugesic or 1-2%
isofluorane), each mouse was positioned within the photoacoustic scanner (SAS;
OptoSonics, Inc or Nexus128; Endra, Inc) so its tumor was at or near isocenter, and
scans were obtained at 10 or more wavelengths throughout the near infrared spectral
range (690-940 nm). Each set of acquired data was reconstructed for each wavelength
(0.1 x 0.1 x 0.1 mm3 voxel size) implementing a 3-D filtered backprojection algorithm
and co-registered across wavelengths (AFNI) to correct for small shifts or movement
between scans. Corrections to the image intensities were performed to account for
variations in the photon fluence emitted by the laser/OPO source as a function of the
wavelength, the beam profile at the surface of the tumor, and the photon attenuation
within water and tumor. The corrected spectral information was fit to a linear
combination of the oxy- and deoxy-hemoglobin absorption spectra implementing a
nonlinear multivariate fitting routine based on Levenberg-Marquardt least squares
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obtained to determine and validate the insertion of the Oxylite probe. The
corresponding SaO2 at needle insertion locations were estimated from the PCT-S
spectral images. Given the spatial sampling of the Oxylite probe is approximately 0.3mm,
SaO2 images were rebinned to 0.3mm prior to determining SaO2 levels. The SaO2 (PCTS) and pO2 (OxyLite probe) measurements were fit to Hill’s equation to determine n and
P50 of the tumor. Next, the hemodynamic parameters obtained from PCT-S and DCE-CT,
in combination with metabolic rates from the literature (M0), was used as inputs into
the MPO2 model to calculate pO2. The correlation and linear regression analysis of
OxyLite pO2 and MPO2 pO2 was performed.

Figure 5.2.4.1: A 1.0 mm3 yellow cubic ROI was placed at position along a straight line
through the center of the tumor, which approximates the actual position of the OxyLite
probe (red).
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5.3.2 Comparing pO2 Measurements Using MPO2 Model and OxyLite Probe in MCF7
Breast Tumors
In figure 5.3.2.1.A-C, the local value for perfusion, fraction of plasma, and fraction of
intracellular volume using DCE-CT are plotted as a function of distance along the central
axis of the tumor. Similarly, the values for the hemoglobin concentration and oxygen
saturation were calculated from PCT-S images (binned to 0.3 mm voxels), see figure
5.3.2.2.A-B. Given the inability to provide absolute position measurements, the imaging
data was shifted along the central axis until overlap with Oxylite probe visually
overlapped. These hemodynamic parameters were used as inputs into the MPO2 model
for pO2 on a voxel-wise basis and compared to OxyLite probe measurements of pO2
(see figure 5.3.2.3.A). The linear regression analysis for all the data points and after
removing the outlier points are displayed in Figure 5.3.2.3.B-C, where the slope, yintercept and p-value are (0.8,0.91), (0.9mmHg, 0.1mmHg), and (0.12, 0.07),
respectively.
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CHAPTER 6.

6.1

MOUSE PANCREATIC TUMOR HYPOXIA QUANTIFICATION

MPO2 as a Means to Monitor the Efficacy of AAT

Over the years, the Stantz lab has been developing new imaging methods and animal
models to study tumor angiogenesis and hypoxia. Dynamic contrast-enhanced CT
method (DCE-CT) developed in this lab provides methods to quantify intra-tumor
pathological parameters, such as blood perfusion, fraction of vessel volume, fraction of
cell volume, and permeability, with high resolution (~ 300 Pm). The high resolution and
fast acquisition of DCE-CT has enabled longitudinal monitoring of tumor progression and
identification of tumor heterogeneity in structure and function aspects [127-129, 192].
In addition, the Stantz lab has developed photoacoustic imaging, a relatively new in vivo
imaging modality capable of quantifying hemodynamic parameters including those
discussed above and those associated with the hemoglobin status of red blood cells, e.g.,
oxygen saturation and hemoglobin concentration.
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Recently, a preclinical study was performed to monitor the efficacy of antiangiogenic
therapy (DC101, a monoclonal antibody blocking VEGFR2 activity) in combination with
radiation therapy (RT), where DCE-CT was used to identify diagnostic parameters
associated with radiation sensitivity in pancreatic tumors [74]. Given the high mortality
rate of pancreatic patients and the inability to improve survival rates over the past 40
years [193, 194], developing new therapeutic regimens and diagnostic tool are urgently
needed. In this section, the MPO2 model is used in an attempt to calculate the oxygen
concentration and profile of mouse pancreatic tumors based on the vascular
physiologies measured by DCE-CT. First, MPO2 model pO2 values were compared to
outcome (tumor growth) in these mouse pancreatic tumor studies. Second, the MPO2
was leveraged to investigate new aspects underlying tumor vascular associated with
normalization.

6.2

Material and Method

6.2.1 Experiment Design
Six groups of nude mice were used to study the influence of AAT on RT in pancreatic
tumors.
1. Controls (n=11). These mice did not receive DC101 or radiation therapy.
2. Radiation therapy cohort (RT; n=4, 12, 6 for 3-, 5-, 7-Gy dose). These mice
received a single fraction of radiation.
3. High-dose DC101 cohort (HD, 150mg/kg; n=11). These mice received an
intraperitoneal (i.p.) injection of 150 mg/kg DC101.
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4. Low-dose DC101 cohort (LD, 40mg/kg; n=10). These mice received an i.p. injection
of 40 mg/kg DC101.
5. High-dose DC101 plus RT (5Gy; n=6). These mice received an i.p. injection of 150
mg/kg DC101, and after one week post AAT, they received a single fraction of
radiation (5Gy).
6. Low-dose DC101 plus RT (5Gy, n=8). These mice received an i.p. injection of 40
mg/kg DC101, and after one week post AAT, they received a single fraction of
radiation (5Gy).

Human pancreatic carcinoma BxPC-3 cells (5x106) were subcutaneously injected into the
flanks of 6- to 8-week-old female athymic nude mice (Harlan Sprague-Dawley), and
allowed to grow to a diameter of 7 to 11 mm. DC101, a gift from ImClone Inc., was
injected intraperitoneally at either a dose of 40 mg/kg (low-dose; LD) or 150 mg/kg
(high-dose; HD). Radiation therapy was applied in a single fraction at a dose rate of
1.6Gy/min (X-RAD 320 Biological Irradiator) using an x-ray tube (kVp of 250KV). Mice of
mono-DC101 groups (at both high dose and low dose) were subject to DCE-CT scan
within 24 hours before injection and imaged again at day 2, 7, 14, and 21 after injection.
Mice from combined therapy group had baseline scan before DC101 injection and 1week post-DC101 injection. Immediately after the second scan, tumors on mice were
treated with 5Gy x-rays. Therapeutic response, the tumor growth delay curve for each
mouse was calculated by measuring the tumor volume every 3 days using calipers [74].
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6.2.2 Impact of Perfusion on Pancreatic Tumor Hypoxia
Blood perfusion was found to correlate to the primary treatment outcome— the
relative tumor growth rate. Medical physicists and oncologists discovered in the mid of
20th century that cell radiation sensitivity depends on oxygen concentration [62, 63]. It is
conceivable that increased blood perfusion owing to tumor vessel normalization leads
to an elevation in oxygen levels to more cancer cells in the tumor, thus enhancing
radiation therapy. In this section, the (1) theoretical pO2 for mice negatively and
positively responding to radiation therapy (NRT and PRT) was compared to pO2 values
based on the MPO2 model, where DCE-CT measurements were used as inputs; (2) the
correlation of the theoretical pO2 and the relative tumor growth rates were compared;
and (3) the impact of vessel tortuosity to tissue oxygen concentration investigated.

Three theoretical schemes were designed to test MPO2 by correlating experimental
observation in the NRT and PRT cohorts to pO2 model values (note, the average
vascular attributes are listed in table 6.2.2.1). After DC101 treatment, blood perfusion in
the PRT cohort remained close to baseline values (0.15 mL/min/g) while in the NRT
group decreased to 0.10 mL/min/g. Since we did not have an accurate measurement of
the hemoglobin concentration from this study, a value of 1.0 g/dL and 3.0 g/dL was used
to compute the pO2 value at the upper and lower ends of this range which was
observed from various types of microvasculature by PCT-S. Two diagnostic parameters –
the average pO2 and hypoxic fraction (HF) – was calculated using the MPO2 model to
evaluate the influence of the vessel physiology on the oxygen status. HF represents the
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percentage of cells in a region of interest falls under the established hypoxic threshold.
A 5 mmHg as hypoxic threshold was adopted in this study, hence HF5 means the
percent of cells in a volume staying under 5 mmHg milieu.

Table 6.2.2.1: Average DCE-CT structural and functional measurements of the control (baseline), the
positive responding tumor (PRT), and the negative responding tumor (NRT).
Baseline
PRT
NRT

Perfusion(mL/min/g)

f-plasma(mL/g)

F-cellular(mL/g)

Hct

SaO2

Tortuosity

0.15
0.15
0.1

0.3
0.25
0.25

0.5
0.5
0.5

0.25
0.25
0.25

0.5
0.5
0.5

1 to 1.2
1 to 1.2
1 to 1.2

6.2.3 Impact of the Fractional Plasma Volume on Pancreatic Tumor Hypoxia
In previous section, the impact on hypoxia relief from blood perfusion normalization
was addressed. To investigate the concomitant decrease in the blood vessel volume on
hypoxia, the oxygen concentration at baseline for NRT and PRT cohorts using MPO2
using the parameters listed in table 6.2.2.1 were simulated.

6.2.4 Impact of Vessel Tortuosity on Pancreatic Tumor Hypoxia
Two distinct aberrant vessel structure features are overwhelming in tumor vasculature:
tortuosity and vessel dilation. Tortuosity refers to the ratio of the sinuous vessel length
to the straight distance between two ends of the vessel segment. Tortuous vascular
path cripples the blood flow which is a dominant cofactor in oxygen transport.
Structural normalization after AAT could correct for either or both abnormalities,
depending on the mechanism of action. DCE-CT can only quantify the total vessel
volume and not the detailed vessel configuration within a voxel. MPO2 model was
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leveraged to analyze the influence of these structural changes associated with vascular
normalization on tumor oxygen concentrations.

In Table 6.2.4.1, four hypothetical scenarios (A-D) were simulated comparing the
tortuosity and vessel dilation on pO2. All other determinants of MPO2 were held
constant. The partial oxygen pressure (pO2) in scenario A served as reference for
scenarios B-D. Scenario B represented the pO2 response from a 20% correction in vessel
tortuosity and scenario C a 20% reduction in the radius. Scenario D and B had identical
volume reduction, but the volume reduction in scenario D was driven by vessel dilation
correction (geometrical normalization) while in scenario B by tortuosity correction
(topological normalization). The oxygen status from scenarios B and D would
demonstrate improved efficiency in the microcirculation with respect to vessel volume
reduction.

Table 6.2.4.1: Four scenarios to compare hypoxia improvement by geometrical
normalization against topological normalization.
Tortuosity
Radius in Pm
Scenario A
10.00
1.2
Scenario B
10.00
1.0
Scenario C
8.00
1.2
Scenario D
9.13
1.2

6.2.5 Simulation of DCE-CT and PCT-S Uncertainty
In previous section, the impact of blood perfusion, the fraction of plasma volume, and
vessel tortuosity on the local oxygen concentration was investigated, where the SaO2
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and Hct were assigned as constant. The influence of the DCE-CT measurement
uncertainty on the precision of pO2 (MPO2-model) was simulated. In this pancreatic
study, blood perfusion and the fractional plasma volume (f-plasma) were the two
variables used in the MPO2 algorithm. In addition to f-plasma, the impact from the
uncertainty in SaO2 and Hct acquired by PCT-S was estimated to better understand the
significance of the oxygen supply capacity in microcirculation to tissue oxygen
concentration. Similar to the approach in section 4.1.8, these input parameters were
varied by +/- 10%.

6.2.6 Mapping Pancreatic Tumor Hypoxia Heterogeneity
Recent studies have demonstrated that the pO2 distribution in tumors is heterogeneous
and may develop regions where tumor cells are exposed to chronic or acute forms of
hypoxia. The implication of chronic and acute hypoxia in cancer therapy complication
and cancer metastasis has recently received attention and currently under intense
investigation[195-197]. MPO2 can be used to display 3D entire oxygen tension
heterogeneity with high spatial resolution. In this section, MPO2 was used to provide
map out pO2 and HF5 distributions. Two mice, one from the PRT and NRT cohorts, were
used to demonstrate the relationship of these parameters in the context of combined
DC101 and radiation therapy. The parametric maps and histogram of the blood
perfusion and fraction of plasma were analyzed and compared between NRT and PRT
tumors.
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6.3

Results

6.3.1 Experimental Observations of Pancreatic Tumor with DC101
Displayed in Figure 6.3.1.1-3 are the three major findings from the pancreatic cancer
study: (1) Combined therapy (DC101 plus RT) showed greater inhibition in the relative
tumor growth rate than mono-therapy (DC101 or RT), which indicated the treatment
efficacy from the combined therapy was better than that of mono-therapy (see black
markers versus gray markers in figure 6.3.1.1); (2) there was not a DC101 dose effect on
tumor growth rates for either of the combined therapies (HD/LD DC101 + RT; gray circle
versus square in Figure 6.3.1.1) or the monotherapies (HD/LD DC101; black circle v.s.
square in figure 6.3.1.1); and (3) the vascular normalization occurred within 48 hours
(see 6.3.1.2-C for detailed illustration).

With regard to the second finding, in addition to the tumor growth rate insignificance
between HD/DC101 plus RT and LD/DC101 plus RT, the average blood perfusion and
fraction of plasma of the combined therapy groups (HD/LD DC101 plus 5-Gy RT) showed
no statistical significant difference as a result of high standard deviation [74]. Cao et. al.
regrouped all mice from the two combined therapy groups based on changes in blood
perfusion, thus forming a positive (radiation) responding tumor (PRT; blood perfusion at
least 15% higher than the baseline perfusion) and a negative (radiation) responding
tumor (NRT; blood perfusion at least 15% lower than the baseline). These two groups
demonstrated a statistically significant difference in their tumor growth rates and in
their average perfusion. The fractional plasma volume for these two groups remained
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statistically equivalent (Figure 6.3.1.2 and 6.3.1.3). In comparison with the RT-only
groups (5- and 7-Gy), PRT showed the lowest tumor growth rate over the 30 days of the
experiment, while NRT had the worst tumor growth rate among four groups (figure
6.3.1.2). Three key conclusions were determined from the pancreatic study: (1) blood
perfusion was a reliable prognostic biomarker to evaluate pancreatic cancer combined
treatment efficacy; (2) there was no clear correlation of blood perfusion normalization
to DC101 dosage (based on body weight) in pancreatic tumors; and (3) DC101
normalized tumor vascular by modulating perfusion and not necessarily vessel
structure as described in this chapter (some care must be taken given the
interconnectivity of these two parameters).

Figure 6.3.1.1: Relative tumor growth comparison of control, mono low-dose DC101,
mono high-dose DC101, mono radiation therapy, DC101-plus-RT (HD and LD). (*P < 0.05,
**P < 0.01 control group to mono RT or DC101; # P < 0.05, ## P < 0.01 DC101 to DC101plus-RT groups; error bar: standard deviation). Reprinted with permission from N.
Cao[74].
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Figure 6.3.1.2: Key physiology adjustment in positive and negative responding group. (A)
Average percentage change with respect to baseline in perfusion and fraction of plasma
of the positive (n=4) and negative (n=5) responding tumors one week post DC101
treatment. Error bars represent the standard deviation (B-C) Relative tumor growth
chart of the positive, the negative, mono-RT at 5Gy/7Gy over time. The valleys in PRT
and 7-Gy RT indicated the onset of vessel normalization. Error bar indicates the standard
deviation. (*P<0.05; **P<0.01). Reprint permission by Cao et. al.[74].

Figure 6.3.1.3: Blood perfusion(F) and fraction of plasma(Fp) histogram of PRT and NRT.
Reprint permission by Cao et. al.
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6.3.2 Simulation Results of Blood Perfusion to Hypoxia
The average pO2 and hypoxia fraction at 5 mmHg (HF5) in PRT, NRT, and the control
groups for all combinations of hemoglobin concentration (CtHb) and vessel tortuosity
are displayed in figures 6.3.2.1 (CtHb = 1.0 g/dL) and 6.3.2.2 (CtHb = 3.0 g/dL). Since the
pattern of two hemoglobin concentrations was similar and the pO2 from 3g/dL
hemoglobin concentration was close to the perivascular pO2 determined by the
microelectrodes[144, 178], the simulation outcomes of high hemoglobin concentration
(3g/dL) was used to demonstrate all following simulation results.

Comparisons between the positive (PRT) and negative (NRT) responding treatment
groups were performed to estimate the impact of blood perfusion on the local oxygen
concentration, while holding the fractional plasma volume constant (0.25mL/g). Note,
the PRT blood perfusion was 50% higher than that of NRT. Shown in Figure 6.3.2.2, the
average pO2 of the PRT cohort at a tortuosity of 1.0 (25.687 mmHg) surpassed the
average pO2 of the NRT cohort (17.032 mmHg). The corresponding improvement of in
the pO2 of the PRT group was 51% higher than NRT. Similar improvement was found in
the other two tortuosity parameters. For the HF5 diagnostic parameter, MPO2
identified an increase in the HF5 of 30% more for the NRT group compared to the PRT
regardless of tortuosity.
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6.3.4 Simulation Results of Vessel Tortuosity to Hypoxia
Tortuosity relates to the topological complexity of network architecture. It is
conceivable that two vasculatures with identical total vessel volume but different
tortuosity yield diverse blood flows and pO2 outcomes. Three tortuosity values were
assigned – 1.0, 1.1, and 1.2 – in MPO2 to investigate the impact of vessel tortuosity on
tissue oxygenation. In all three groups (the control, the PRT, and NRT), MPO2 showed
that a highly tortuous vessel (1.2) reduced the pO2 compared to normal vessels
(tortuosity of 1.0). In the NRT group, the reduction in pO2 due to tortuosity (1.0 versus
1.2) was nearly 14%, while in the PRT and control groups, this reduction was 4%.

6.3.5 Simulation Results of Synergistic Normalization to Hypoxia
Previous MPO2 analysis considered the impact from individual physiological attributes
on the tumor’s pO2. Tortuosity in the PRT was most likely less than the NRT and control
groups, thus the improvement in the pO2 levels between PRT and NRT groups as
reported in the blood flow section should be more than 51%. If DC101 normalized
tortuosity in the PRT group (1.0) but failed in NRT group (1.2), the improvement in the
pO2 was due to the synergy between favorable blood flow and tortuosity and would be
approximately 57%. This improvement should become more significant when the
difference in tortuosity becomes even higher.
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6.3.6 Simulation Results of DCE-CT and PCT-S Uncertainty

MPO2 response to the uncertainty from the fraction of plasma(f-plasma). The simulated
f-plasma uncertainty of 10% in the control, PRT, and NRT was +/- 0.03 mL/g, 0.025 mL/g,
and 0.025 mL/g, respectively. Accordingly, the corresponding lower and upper f-plasma
in these three groups was 0.3 +/- 0.03 (control); 0.25 +/- 0.025 (PRT); and 0.25 +/- 0.025
(NRT). The error bars in figure 6.3.6.1 indicate the resulting pO2 with the lower and
upper f-plasma for hemoglobin concentrations set at 1.0 and 3.0 g/dL and tortuosity set
at 1.0, 1.1 and 1.2. For high or low hemoglobin concentrations, the pO2 difference
between the PRT and NRT groups remained significant for a 1.1 or 1.2 tortuosity value.
The pO2 difference for a tortuosity of 1.0 between the control and PRT group became
insignificant, while either one with respect to NRT remained significant.
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Figure 6.3.6.1: Sensitivity test of fraction of plasma in MPO2. The upper and lower value
of an error bar is determined by MPO2 with upper and lower f-plasma (1.1 and 0.9
times of the average f-plasma).
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MPO2 response to the uncertainty from oxygen saturation (SaO2). An average SaO2 of
0.5 was assigned to all three groups, and a 10 percent uncertainty in SaO2 was
investigated (e.g., a value of 0.45 and 0.55 for the lower and upper limits). This
uncertainty in the SaO2 (figure 6.3.6.2) demonstrated a nonlinear response, but did not
nullify the significance in pO2 difference between PRT and NRT at any tortuosity. This
result was expected because the blood perfusion for the PRT group was 50% higher than
that of NRT after DC101 treatment, where the tissue pO2 in oxygen concentration
improvement resulting from the robust increase in blood perfusion surpassed the
concern of the 10 percent SaO2 uncertainty.
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Figure 6.3.6.2: Sensitivity test of SaO2 in MPO2. The upper and lower value of an error
bar is determined by MPO2 with upper and lower SaO2 (1.1 and 0.9 times of SaO2 = 0.5).

MPO2 response to the uncertainty from hematocrit (Hct). Similar to SaO2, the
hematocrit (Hct) was assigned a value of 0.25 based upon the observation from PCT-S
and literature. The uncertainty test of Hct was identical to f-plasma and SaO2. In Figure
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6.3.6.3, the 10 percent uncertainty in the hematocrit had the highest impact on pO2 in
the control group, and minimum influence to the pO2 in the positive responding tumors.
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Figure 6.3.6.3: Uncertainty test of Hct in MPO2. The upper and lower value of an error
bar is determined by MPO2 with upper and lower Hct(0.225 and 0.275).

6.3.7 Tortuosity Normalization vs. Dilation Normalization
Displayed in Table 6.3.7.1 is a summary of the oxygen level response from (1) 20%
tortuosity reduction, (2) 20% dilation reduction, (3) competition of tortuosity and
dilation correction under the condition of even volume reduction. These results show
that for the same percent correction, the vessel tortuosity was more efficient than
correcting for the vessel dilation when trying to increase tumor oxygen levels. Note, the
reduced vascular volume based on the 20% correction in dilation (vessel radius) is 30%
more than 20% tortuosity correction. The same observation was found under the
condition of equal volume reduction. For example, a 3.0 g/dL hemoglobin concentration
(scenario D; topological normalization) improved the average oxygen level 20% with
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respect to the reference (scenario A), while scenario B (geometrical normalization)
improved oxygen levels by only 8%. In terms of HF5, topological normalization reduced
hypoxic fraction by 19%, while geometrical normalization by only 7%. These findings
support the idea of the diverse mechanisms contributing to AAT-induced vessel
normalization.

Table 6.3.7.1: Oxygen response of various normalization mechanisms
Result of Hb = 1.0 g/dL
(HF5, Average pO2)

A: R=10 Pm, tort = 1.2
B: R=10 Pm, tort = 1.0
C: R=8 Pm, tort = 1.2
D: R=9.13 Pm, tort =
1.2
A: R=10 Pm, tort = 1.2
B: R=10 Pm, tort = 1.0
C: R=8 Pm, tort = 1.2
D: R=9.13 Pm, tort =
1.2

(0.836, 7.147 mmHg)
(0.805, 8.573 mmHg)
(0.807, 8.570 mmHg)
(0.824, 7.75 mmHg)

% change of HF5

% change of ave. pO2

3.72 %
3.47 %
1.4 %

-20%
-20%
-8.4%

Result of Hb = 3.0 g/dL
(0.515, 21.41 mmHg)
(0.417, 25.69 mmHg)
19%
17%
(0.425, 25.57 mmHg)
(0.478, 23.17 mmHg)
7%

-20%
-19%
-8%

6.3.8 Oxygen Concentration Maps of the Pancreatic Xenograft Tumors
In Figures 6.3.8.1.A-D, the four montages are summarized for a single mouse. The top
panel of each montage displays the perfusion and f-plasma histograms of the two
tumors (red arrow indicated the location of the average value); the middle panel
displays the tumor blood perfusion and f-plasma maps (DCE-CT); the bottom panel
displays the theoretical pO2 and HF5 distribution as determined by the MPO2 model.
Displayed in Figures 6.3.8.1.A-D are the abnormal heterogeneous blood perfusion and fplasma distribution in the pancreatic tumors. In the PRT mouse (figure 6.3.8.1.A-B),

117
tumors one-week after DC101 treatment showed a similar distribution of perfusion and
f-plasma relative to baseline values, but a reduced the spread in histogram. In the NRT
mouse (Figures 6.3.8.1.C-D), DC101 significantly reduced both the average blood
perfusion and the spread in histogram (or heterogeneity in distribution map).

The wide range in f-plasma and low variance in f-plasma frequency distribution at
baseline suggests the existence of highly chaotic vessel structure in tumor. In each PRT
tumor, the perfusion distribution at baseline (prior to DC101 treatment) was similar to
that at week-one (one week post DC101 treatment); however the perfusion distribution
of the NRT tumors at week-one was different from baseline.

The fractional plasma volume (f-plasma) at baseline and week-one post-DC101 indicated
a reduced overall vessel volume but maintained a spatial heterogeneity in both NRT and
PRT mice. Perfusion in the PRT mice did not decrease post-DC101 treatment as shown in
the histogram, where the sub regions in tumor with high perfusion (hot spots) moved to
different part of tumor and the heterogeneity appeared to be unchanged between the
baseline and the week one groups. The map of HF5 tracked that of pO2. DC101
alleviated the global oxygen concentration in the tumor; however, some regions clearly
remained highly hypoxic, subsequent influence from those highly hypoxic domains to
tumor metastasis is unknown and requires further investigation.
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Figure 6.3.8.1.A: Positive responding group: Mouse 174302.M1
Right tumor(RT) perfusion and f-plasma at baseline and
week one

Left tumor(LT) perfusion and f-plasma at baseline and week
one
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Figure 6.3.8.1.B: Positive responding group: Mouse 174302.M3
Left tumor(LT) perfusion and f-plasma at baseline and week
one
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Figure 6.3.8.1.C: Negative responding group: Mouse 174303.M1
Left tumor(LT) perfusion and f-plasma at baseline and week
one
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Figure 6.3.8.1.D: Negative responding group: Mouse 174303.M3
Left tumor(LT) perfusion and f-plasma at baseline and week
one
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Figure 6.3.8.1.A-D: Histogram and distribution of key MPO2 inputs and outputs. Each
figure displays a single mouse DCE-CT functional quantification and the corresponding
simulated tumor pO2 status at baseline(pre-DC101) and one week post DC101
treatment. Each figure is composed of three sections: perfusion/fraction of plasma
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volume(f-plasma) histogram on the top; perfusion(F)/f-plasma montage at the middle;
simulated pO2/HF5 montage on the bottom. The middle montage demonstrates the
perfusion and f-plasma map of two tumors in a mouse determined by DCE-CT in single
voxel resolution; the top histogram displays the perfusion and f-plasma value
distribution from all voxels in the tumor shown in the middle montage. Two histograms
on the left of histogram panel represent the blood perfusion in voxel at baseline and
week one; two histograms on the right show the distribution of the fraction of plasma in
voxel. The red arrow in the histogram indicates the location of the average value from
all voxels. The bottom montage displays the simulated pO2 and HF5 in each voxel by
MPO2 adapting the corresponding voxel perfusion and f-plasma inputs. In the title of
each figure, LT represents left tumor; RT: right tumor; WK1: week one.
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CHAPTER 7.

7.1

DISCUSSION

Mathematics in Biology and Medicine

Mathematics is widely used in the fields of Physics, Chemistry, and Engineering.
Mathematics in theoretical Physics and Chemistry is no longer used merely as a
technique aid but as a conceptual tool for the foundation of new hypotheses and the
parameters to test these hypotheses. In the Life Sciences, mathematicians and biologists,
including medical scientists have a long history working together. In comparison to
other scientific fields, mathematical biology or biophysics is highly interdisciplinary
which requires an understanding of both biology and mathematics, where systems are
often nonlinear and complex, involve multiple signaling pathways or biomechanisms,
and far from a simplified ideal system. Moreover, experimental verification of these
mathematical models of these biological systems are often difficult due to technical
challenges to obtain data noninvasively, the inability of identifying relevant measurable
parameters and bridging the microscopic and macroscopic, and the need to
simultaneously acquire several parameters due to complexity of the system. In spite of
these challenges, significant progress in understanding and solving fundamental
biological problems has and will continue to occur by concurrently developing and
advancing theoretical biophysical models and technology.
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7.1.1 Using GPO2 as a Standard to Validate MPO2
In this study, a novel integrative approach was proposed to fuse multiple in vivo imaging
parameters based on mathematical models capable of quantifying tumor hypoxia with
high spatiotemporal resolution. The biophysical presumption underlying this approach
states that a single vessel with multi-functional attributes can adequately represent the
real microvasculature, and if the voxel was small enough, the pO2 calculated using this
model (MPO2) would approach the actual pO2 exerted by the local vasculature (see
figure 3.1.5.1). The key to the success of this methodology relies on an accurate
measure of the tissue’s vascular hemodynamics and metabolic rate within a single voxel.
Recent advances in the spatial resolution and acquisition speeds of in vivo imaging can
realize such a methodology. However, testing and validating such a model is difficult,
requiring the measurement and co-localization of vascular physiology, hemoglobin
status, and oxygen metabolic rates. To the best of our knowledge, this has yet to be
accomplished. To overcome this obstacle, an alternative approach was developed
where the pO2 was calculated using a network-based model approach –
Green’s function model (GPO2) – and used as a standard or reference. This reference
model was compared to the modified multivariate Krogh model (MPO2), which was
used for image fusion. Validation of MPO2 mathematical model by GPO2, another
mathematical model based on Green’s function solution, invites some concerns, but
again this is a logical first step to test the feasibility (limitations) of the proposed MPO2
technique. Green’s function considers every vessel segment contribution to the local
oxygen concentration level, highlighting the importance of vessel geometry and
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topology to oxygen transport. A second, or more important feature, is that the
computed pO2 based on GPO2 was verified by the experimental measurement [198]. To
date, this is the only report directly comparing experimental data and theoretical
oxygen transport models. Yet, the microvessel structure and functional parameters (or
attributes) used in this study were acquired by the integration of the intravital confocal
scanning microscopy with other optical techniques, where the intrinsic photon
penetration depth is limited to the superficial vasculature. Given that a tumor’s
vasculature might be structurally and functionally different from those near the
periphery, these results are only representative of a tumor.

7.1.2 Discrepancy Between the PO2 Calculated from MPO2 and GPO2 Models
In Figure 4.3.3.2, the correlation between GPO2 and MPO2 was dependent on the voxel
size or spatial resolution of the imaging system. Voxel size in the range from 50 to 200
Pm showed a better coefficient of determination (R2) compared to 250 and 300 Pm in a
tumor. For larger voxels sizes, the increased vascularity degraded the correlation
between pO2 values. Increasing the complexity of the model (two parallel cylinders) did
not improve these results (see Appendix for method of a multi-vessels MPO2 model).
Unlike the tumor, there were no outliers for 50 Pm voxels in the brain tissue. This
discrepancy reflects the underlying difference between the physiological and
pathological angiogenesis. The average inter vessel distance in the tumor was higher
than that in the normal vessel network of the brain. In the tumor, two outlier groups
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were observed: (1) the overestimated group, of which MPO2 was greater than GPO2,
and (2) the underestimated group, of which MPO2 was lower than GPO2. The location
of all outlier voxels was identified and highlighted the inappropriate assumption in the
boundary conditions used in MPO2. Most of the overestimated voxels enclosed one
vessel segment imperceptibly clipping through the voxel corner and the underestimated
50-Pm voxels were filled with several vessels or a large vessel (arteriole). Another
underestimation scenario occurred when the voxel resided nearby the large vessel
segments. Given that the largest tumor vessel diameter was close to 60 Pm and 13
percent of the tumor vessel segments possessed a diameter greater than 30 Pm, it is
conceivable that a voxel near to the large vessel segments results in a significant
amount of oxygen diffusion from a neighboring voxel (or arteriole). To correct the
outlier problems, a nearest neighbor algorithm was implemented, which formed a new
boundary condition and significantly improved the correlation of the outliers. The linear
regression displayed in Figure 4.3.4.2(A) demonstrates the significant improvement in
the results.

A sensitivity analysis was performed where a systematic change in each parameter was
plotted while holding all other parameters constant, see figure 4.3.2.1. Blood perfusion,
oxygen consumption, oxygen saturation (SaO2), and hemoglobin concentration (CtHb)
all influenced oxygen transport in a similar fashion and magnitude. Overall, the vessel
diameter had the least influence, while the importance of SaO2 and hemoglobin
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concentration underlines the importance of photoacoustic spectroscopy (PCT-S) in
predicting pO2. New contrast-enhanced PCT-S imaging currently being developed in the
Stantz lab will provide simultaneous acquisition of the vessel structure, physiology in
addition to the oxygen saturation and hemoglobin concentration critical for MPO2
determination of pO2. This can reduce image acquisition time and bypass the
uncertainty from image co-registration procedure. However, the importance of oxygen
metabolism remains critical in determining local oxygen concentration. Cellular density
in a tumor can be highly heterogeneous. Since MPO2 considers the fraction of cells from
DCE-CT (fraction of cell volume = 1 – fraction of vessel volume – fraction of interstitial
volume), MPO2 can provide a more accurate measure of pO2 than Green’s function
algorithm. In these simulations, the cancer cell metabolic rate was assumed to be either
at its maximum or dormant, which has yet to be validated, and can contribute to the
uncertainty in the pO2. In chapter 4, the potential error (precision and accuracy) in pO2
due to measurement error in perfusion and fractional plasma volume was investigated.
The average coefficient of variance (CV) of pO2 due to blood perfusion and fraction of
vessel volume error was close to 3.3% and 7.0% and considered relatively small,
assuming a 20 percent uncertainty in these measured parameters (based on commercial
high-resolution CT imaging scanners).

The simulations performed in this study demonstrate the feasibility of the MPO2
method to quantify oxygen concentration and obtain hypoxic fractions in a tumor, but
with some limitations. For example, the voxel size or spatial resolution should ideally be
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200 Pm or smaller. By including 20 percent noise into the parametric images, which is
consistent with measured values, the linearity and variance remained less than 7
percent. Together with the result from sensitivity test, future oxygen profiling
experiments should focus on PCT for both physiological measurements (DCE-PCT) and
hemoglobin status, SaO2 and CtHb (PCT-S). Replacing DCE-CT has two main advantages,
better spatial resolution and mitigating unnecessary dose from ionizing radiation;
however, quantification remains unproven in DCE-PCT and in vivo imaging remains
limited due to signal loss at depth.

7.2

In vivo Validation of MPO2 Using the OxyLite Oxygen Sensor

In specific aim 1, the MPO2 model was investigated at various voxel sizes. For voxel sizes
ranging from 500-200 Pm, a correlation between the pO2 based on the microscopic
measurements and Green’s function solution to oxygen transport and in vivo imaging
and MPO2 model. For specific aim 2, the voxel size implemented was set to 300 Pm,
which was based on the range or field-of-view of the Oxylite probe and the in vivo
imaging modalities used in this study. As a first step, To calibrate the OxyLite probe, pO2
and SaO2 in blood was obtained using the OxyLite probe and co-oximeter, respectively,
from which the dissociation curve associated with the red blood cells was plotted, with
little scatter in the data. Both Hill’s coefficient, n, and P50 (2.26 and 23.4 mmHg) are
consistent with reported values [135], validating both the OxyLite probe and technique
against a Gold Standard (co-oximeter). Within the tumor, reductions in P50 were
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observed (17.2 and 20.7 mmHg) are consistent with microenvironmental factors
influences the dissociation curve, such as acidosis (reduced pH). The acidosis of tumor
was arguably responsible for low n and P50; however, additional experiments will be
required to confirm this hypothesis.

Next, DCE-CT and PCT-S scans were acquired to determine the key vascular physiological
arguments to MPO2 model. Ideally, both DCE-CT and PCT-S should be acquired within a
short time to minimize cycling effects and improve the accuracy and precision of pO2. IN
this study, these measurements were 30-90 minutes apart. Although the measurements
of DCE-CT and PCT-S were not quantified simultaneously, the overall trend (P<0.1) of
MPO2 to OxyLite pO2 was observed. The high deviation of blood perfusion (figure
5.3.2.1.A) and hemoglobin concentration (figure 5.3.3.2.A) at the both ends (point 1 and
10) resulted in high discrepancy between MPO2 and OxyLite pO2. Other factors
affecting the accuracy and precision include the accuracy at which PCT-S, DCE-CT, and
OxyLite probe can be spatially co-localized and the influence of a 300 mm range (or
voxel size) on MPO2.

7.3

MPO2 Analysis on PRT and NRT Tumors Post DC101 Administration

Cao et. al. used DCE-CT to longitudinally monitor the vascular and tumor physiology in
the mouse xenograft pancreatic tumors subject to mono AAT (DC101) or radiation
therapy or both. They adapted a blood perfusion threshold to regroup the mice
receiving the combined therapy (AAT plus RT) into the positive responding group (PRT)
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and the negative responding group (NRT). The average blood perfusion of the positive
responding tumor (PRT) was 50% higher than that of the negative responding tumor
(PRT); the fraction of plasma of PRT showed statistically equal to that of NRT. Blood
perfusion is a robust surrogate marker since it significantly correlates to the primary
outcome in this study-- the relative tumor growth rate. The finding suggested that
increased blood in PRT improves the oxygen concentration in tumors which enhances
the following radiation sensitivity to kill tumor cells. This study also provided an
opportunity to apply MPO2 to calculate tumor oxygen concentration. Although there
were no SaO2 and Hct measurements, we used SaO2 = 0.5 and Hct = 0.25 in MPO2
simulation, which were close to the PCT-S observations of many tumors in our lab.

The theoretical assessment supported the Cao’s findings that blood perfusion is a
reliable surrogate marker to predict the combined therapeutic outcome of pancreatic
xenograft tumors with DC101 as AAT agent, and proved the significant tumor hypoxia
relief due to the increased blood flow. MPO2 model showed that the increased blood
perfusion in PRT (50% more than PRT) significantly elevated the oxygen concentration
(57% more than PRT) that the concern from 10% DCE-CT or PCT-S measurement
uncertainty (perfusion, f-plasma, SaO2, Hct) can even be ignored. The real oxygen level
difference between NRT and PRT could be higher since the tortuosity difference
between two groups is most likely greater than 20%. The montages in figure 6.3.8.1.A-D
showed the high heterogeneity in tumor oxygen concentration. We speculate that more
negative responding tumors might become the positive responders if intensive narrow
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radiation beams are applied only to the highly hypoxic local regions shown on the
oxygen map instead of the entire tumor.

7.4

Perspectives in Vessel Normalization

Vessel normalization hypothesis proposed by Dr. Jain provides a sounding explanation
to the improved efficacy from the combined therapy (AAT plus RT or AAT plus
chemotherapy) by easing off tumor hypoxia; many preclinical and clinical investigations
demonstrate the evidences of the normalized vessels, e.g. the increased blood perfusion,
decreased plasma volume, reduced interstitial pressure (IFP) in solid tumors, and more.
However the detailed normalization mechanisms remain unanswered and required
further investigations. For example is there only one mechanism responsible for all
tumor vessel structural and functional normalization? Or are there separated driving
forces controlling individual aspects of normalization? Does tumor vessel normalization
occur heterogeneously? How would this normalization heterogeneity affect the patient
survival rate and correlate with tumor hypoxia? Some solid tumors showed the clear
structural normalization concomitant with functional normalization; some appeared to
suggest that two normalizations were decoupled (e.g. our pancreatic tumor study);
some solid tumors did not respond to AAT at all [199, 200]. What are the underlying
factors responsible for various normalization outcomes? In this study we used MPO2 as
a concept tool to investigate two structure normalization modes—the topological
normalization mode to correct tortuosity and the geometrical normalization mode to
correct vessel diameter. We found normalizing vessel network tortuosity was more
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efficient than normalizing vessel segment diameter. If there was a separated pathway
controlling vessel tortuosity normalization, perhaps targeting this mode would yield
superior survival rate than targeting the vessel diameter normalization.

Blood perfusion in a vascular network is related to the pressure gradient between the
arterial and venuous end, the plasma viscosity, and structure resistance of the vessel
network. Tortuous tumor vasculature has high structure resistance which contributes to
the stagnant blood flow. Hence we would expect structure restored vasculature induced
by AAT should lead to the increased blood flow. Ideal vessel normalization should
restore most abnormal attributes of tumor microvasculature in a period of time (dilation,
tortuosity, decreased blood flow, permeability, e.t.c). In pancreatic tumor the blood
perfusion difference between NRT and PRT reached statistical significance, not the
fraction of plasma volume. Our theoretical work in comparing the pO2 improvement
from the geometrical and topological normalization suggested that vessel normalization
in NRT might correct more the vessel diameter than the vessel tortuosity. The
topological normalization was more active than the geometrical normalization in PRT. In
other word, more vessel tortuosity in PRT group possibly was normalized than in NRT
group. Both NRT and PRT groups had similar vasculature volume reduction after DC101
administration, but less tortuous vessel network in PRT offers reasonable explanation to
the increased blood perfusion and oxygen concentration. Idea of arteriole network
normalization can provide another route to increase blood flow. Since the arteriole
network of microcirculation controls the blood flow rate in the capillary network,
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normalizing the abnormal arterioles including restoration of smooth muscle coverage
and autoregulation feedback mechanism should improve the blood flow in
microcirculation and the subsequent oxygen level in tissue.

Microcirculation composed of arteriole, capillary, and venule network is a complicated
and interactive system. We found that restoration of tumor microvasculature seems to
involve several modes to normalize various parts of the network and functions. Many
investigations showed that the arteriole not only controls the blood flow to capillary
network but involves direct oxygen delivery to tissue. The impact to local oxygen
concentration from the arteriole network should be at least as dominant as the capillary
network. Perhaps there is hierarchy in vessel normalization; normalization begins at
arteriole network might yield preferred antiangiogenic outcome than normalization
starts at capillary network. Henceforth the capability to further quantify functions and
structures for the arteriole network will benefit our understanding in the outcome of
antiangionetic therapy.

7.5

Future Perspectives

Hypoxia is a critical factor in the life of tumor and the cancer therapeutic outcome.
Hypoxia is also critical to other disease progression, such as macular degeneration,
diabetes retinopathy, chronic kidney and liver fibrosis formation. What is more, we
began to realize the pathological significance of hypoxia etiology, distribution, and
dynamics in the disease formation and complication to other molecular pathways in
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progression. Therefore capability to quantify hypoxia in high fidelity and accuracy will
assist to answer those questions and to develop new therapeutic interventions to
prevent or to manage the diseases. In this study we proved the validity of our novel
approach to quantify tissue pO2 with in vivo functional imaging and mathematical
modeling; we also showed the initial success that theoretical MPO2 prediction agreed
with the experimental findings of the antiangiogenic drug on pancreatic xenograft
tumors. In this section we proposed four future directions to further improve or extend
oxygen transport modeling in hypoxia research.
Animal model. We used Green’s function algorithm to evaluate the tissue oxygen profile
determined by the structure and function of microcirculation. The detailed vessel
structure and function were acquired by inoculating tumor cells in window chamber
model. Window chamber model is laborious and technical challenging. The success in
the implementation is highly determined by the skill of the surgeon. What is more, the
tumors can only grow in the chamber with very limited depth (< 200 Pm), which raises
the concern how much the tumors in window chambers is relevant to the true
subcutaneous tumors on host. Retina is a very transparent tissue in the back of eyes,
tumor growing in retina has no limitation in depth and the tumor cell induced
vasculature is easily to observe. Tumor cell inoculation in retina provides another animal
model to study detailed structure and function of tumor-induced angiogenesis[201, 202].
Accuracy improvement in large voxel size. Simulation showed the excellent correlation
existed only voxel size was in range of 50 to 200 Pm and deteriorated as voxel size
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increased. While this is expected, developing a verified correction formula for voxel size
greater than 250 Pm can extend this method to in vivo functional imaging modalities
with lower spatial resolution to estimate hypoxia distribution in tumor.
Measurement of SaO2 and CtHb. SaO2, CtHb, and blood flow are highly related to the
oxygen concentration in blood as shown in the sensitivity comparison in chapter 4. In
pancreatic study, we had structural and hemodynamic parameters from DCE-CT with a
reasonable average value of SaO2 and CtHb in calculation. Tumor vessel is known for
heterogeneity in both function and structure. Studies showed identical diameter tumor
capillaries can carry diverse RBC flow, which suggested the corresponding SaO2 and
CtHb could fluctuate as well [146, 203, 204]. Hence the accurate measurement of SaO2
and CtHb are needed in future xenograft tumor experiment to reach more accurate
tumor pO2 prediction.
Development of Dynamic contrast-enhanced 3D photoacoustic imaging. Photoacoustic
imaging is an emerging hybrid in vivo imaging modality. Dynamic contrast-enhanced 3D
photoacoustic imaging (DCE-PCT) will provide most of key vascular physiology in oxygen
transport in one experiment. Some preliminary investigation has begun to address the
capability and application of this new technology in tumor hypoxia [205-207]. Acute
hypoxia has shown correlation to angiogenic treatment efficacy in some solid tumors.
The fast scan capability of DCE-PCT will assist to identify short-period acute hypoxia
dynamics and its consequence in tumor progression and metastasis.
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Multi-Vessels MPO2 Modeling

Multi-vessels MPO2 model is the modification of single vessel MPO2 model. The
procedures of obtaining voxel vascular inputs (fraction of vessel volume, blood
perfusion, hct, and SaO2) are identical. Single vessel model evaluates the pO2 in a voxel
by placing the vessel at the center of the voxel; multi vessels are distributed
symmetrically in the voxel (see figure A). In multi-vessels model, the total vessel volume
and blood perfusion are equally divided into the multi-vessels. For instance, in a twovessels model each vessel blood perfusion is half of the total voxel blood perfusion; each
vessel volume is half of the total vascular volume. SaO2 and concentration of
hemoglobin of each vessel remain unchanged as the total voxel SaO2 and hemoglobin
concentration. The pO2 at any point inside voxel is the superposition from each
individual vessel.
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